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ABSTRACT 
 
The mammalian brain expresses two angiotensin II specific receptors, the 
angiotensin II type 1 (AGTR1) and type 2 (AGTR2). Studies in humans and mice 
indicate a possible role for AGTR2 in learning, memory and behavior.  However,  
AGTR2 gene function in the brain, and the molecular mechanisms by  which 
AGTR2 exerts its physiological action, remains elusive. This study examines the 
possible role of AGTR2 in the developing brain and in brain function by employing 
three different approaches. 
  To identify genes in the developing brain that depend on AGTR2 function, 
a microarray analysis was conducted that compared the gene expression of Agtr2-/y  
mouse brains to normal controls at embryonic day 15 and postnatal day 1.  Genes 
involved in microtubule regulation, cell adhesion and glutamate metabolism were 
found to be up-regulated in Agtr2-/y mouse brains.  These results suggest that AGTR2 
may contribute to the developing brain by influencing cell morphology and synaptic 
connectivity. 
  Using a yeast two-hybrid system, the amino-terminal extracellular domain 
and carboxy-terminal intracellular domain of AGTR2 were screened against a human 
fetal brain cDNA library to identify AGTR2 interacting proteins. Three novel 
AGTR2 interacting proteins, ASMTL, GNB2L1 and NGLY1 were identified.  
Lastly, a brain-specific isoform of a previously identified AGTR2 interacting 
protein, ATIP, was explored as a potential candidate gene for mental retardation. 
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Limited screening of the ATIP gene in 80 patients with mental retardation identified 
two non-pathogenic sequence variants but no disease causing mutations.   
In summary, this study unveils several functional classes of genes as potential 
downstream targets of AGTR2 and identifies three new AGTR2 interacting proteins 
in the developing brain. Further functional studies of the newly identified AGTR2 
interacting proteins and some of the genes influenced by AGTR2 may provide clues 
to AGTR2-mediated signaling in the developing brain and in brain function. 
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PREFACE 
 
 
 Mental retardation (MR), defined by an IQ score less than 70, affects 
approximately 1-3% of the human population (Chelly and Mandel 2001).  The causes 
of MR are many, and in up to 40% of cases the cause is unknown (Chelly and 
Mandel 2001).  When the cause is known, mental retardation can result from prenatal 
insults, environmental factors, injuries and genetic causes.   The genetic component 
of MR likely includes mutations in a large number of genes distributed throughout 
the genome.  X-linked mental retardation is the most common cause of MR in males 
(Stevenson 2005). 
 The role of angiotensin II (Ang II) in the renin-angiotensin system (RAS) has 
been well characterized as an enzyme-neuropeptide system in the brain, as well as for 
its role in blood pressure control and fluid homeostasis.  The action of the Ang II 
peptide is primarily mediated by its two receptors, Angiotensin II type 1 receptor 
(AGTR1) and Angiotensin II type 2 receptor (AGTR2).  The RAS has been shown 
to regulate sensory information, learning and emotional response (von Bohlen und 
Halbach and Albrecht 2006). Several components of the RAS have been implicated 
as having roles in brain development and function.  Mutations in the AGTR2 gene 
have been found in individuals with MR (Vervoort et al. 2002; Ylisaukko-ojo et al. 
2004), and a family with X-linked MR and epilepsy has been found to have a 
mutation in the renin receptor (Ramser et al. 2005).  
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All components of the RAS are present in several areas of the body including 
the kidney, blood vessel walls, heart and brain (Lavoie and Sigmund 2003).   In the 
classic RAS, angiotensinogen is converted to angiotensin I by renin.  Angiotensin I  
is cleaved by angiotensin converting enzyme (ACE) to make angiotensin II (Figure 
P.1).   Angiotensinogen can also be cleaved by cathespin D or tonin to make 
angiotensin II.   Cathespin G, chymostatin-sensitive angiotensin II generating 
enzyme (CAGE), and chymase can also cleave angiotensin I to make angiotensin II 
(Lavoie and Sigmund 2003; von Bohlen und Halbach and Albrecht 2006). Ang II is 
likely the first neuroactive form of the angiotensins.  Other neuroactive angiotensins 
include angiotensin IV and angiotensin (1-7) and are produced by the actions of 
other enzymes (von Bohlen und Halbach and Albrecht 2006).   
 Physiologically AGTR2 has been shown to balance the actions of AGTR1 
(Hein et al. 1995; Ichiki et al. 1995; AbdAlla et al. 2001).   AGTR2 has been shown 
to inhibit AGTR1 actions by directly binding to AGTR1 (AbdAlla et al. 2001).   The 
role of AGTR1 is very well characterized, but the functions of AGTR2 remain 
elusive.  The purpose of this study is to elucidate the physiological function of 
AGTR2 in the developing brain. 
  The RAS mediates the expression of AGTR1 and AGTR2 by the level of 
angiotensin II produced, and thus the signaling cascades controlled by each 
respective receptor.   Stimulation of AGTR1 raises blood pressure, increases cellular 
Ca2+ , depolarizes sodium channels and contributes to cell proliferation (Allen et al. 
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1998; Berry et al. 2001).  Conversely, activation of AGTR2 lowers blood pressure,  
hyper-polarizes sodium channels and induces apoptosis (Berry et al. 2001).  Different 
signaling cascades are mediated by angiotensin II depending on whether it is bound 
by AGTR2 or AGTR1.  Binding of  angiotensin II  to AGTR1 causes endocytosis of 
AGTR1 but not AGTR2 (Hein et al. 1997).   AGTR1 induces phosphorylation by 
tyrosine kinase and up-regulates Map kinases (MAPK), which up-regulates  
transcription of various genes affecting cell proliferation (Berry et al. 2001).  AGTR1 
also induces vasoconstriction via the phosphatidyl inositol pathway (Berry et al. 
2001).  Conversely, AGTR2 through the activation of protein phosphatase 2A 
(PP2A),  inhibits MAPK expression.    Through stimulating ERK phosphatase, 
AGTR2 also promotes apoptosis as well as vasodilation through nitrous oxide 
synthetase and phospholipase A2 (Berry et al. 2001).  AGTR2 has also been shown 
to regulate cell growth (Goto et al. 1997). These functions are summarized in Figure 
P.1. 
Functional studies of AGTR2 in neuronal cells suggest it has a role in 
apoptosis and cell differentiation.  AGTR2 has been found to mediate apoptosis in 
PC12W and R3T3 cells (Yamada et al. 1996)  AGTR2 has been localized to neurons 
but not glial cells and has been shown to influence morphology of several cell types 
including NG-108-15, PC12W and rat neuronal cell lines (Gendron et al. 2003). Its 
effects on neuronal growth and differentiation are complex.   In PC12W cells, 
AGTR2 was found to up-regulate MAP2, polymerize beta-tubulin levels and down-
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regulate MAP1B protein levels.  MAP2 has been associated with elongation of axons  
(Shea and Flanagan 2001).   Thus a possible role for  AGTR2 in nerve regeneration 
and cell differentiation was suggested (Stroth et al. 1998).   
 
 
Figure P.1  The angiotensin II receptors signaling cascade.  The physiological 
functions affecting the developing brain are highlighted in orange. 
 
Using NG-108-15 cells, Gendron and associates (1999) found that AGTR2 
stimulates neurite outgrowth via an increase in MAPK activity and a decrease in 
p21ras  activity in a time dependent manner.  The inhibition of protein kinase C 
(PKC) by AGTR2 has also been shown to inhibit cell proliferation by PKC 
inhibiting p21ras  and then up-regulating Rap1 and the p42/p44mapk  pathway to allow 
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neurite elongation (Beaudry et al. 2006).   AGTR2 has also been shown to stimulate 
neuronal differentiation by its association with MMS2 and a complex of ATIP and 
SHP-1 in rat neuronal cells (Li et al. 2007).   
Both receptors are expressed in the hippocampus, the cingulate cortex, parts 
of the amygdala, the anterior thalamus, the paraventricular nucleus, the supraoptic 
nucleus,  the superior and inferior colliculi,  the locus coeruleus, the inferior olive 
and the vagal nucleus (reviewed in von Bohlen und Halbach and Albrecht 2006).  
AGTR2 is uniquely expressed in the lateral septal area, habenula, centromedial 
thalamus, medial geniculate nucleus, reticular nucleus, ventral segmental area, 
hypoglossal nucleus, motor trigeminal nucleus and the cerebellum (von Bohlen und 
Halbach and Albrecht 2006). 
In the mouse fetus, expression of AGTR2 has been shown to be relatively 
higher and more diverse in the developing brain than in adulthood (Johren and 
Saavedra 1996; Nuyt et al. 1999; Saavedra 2005).  Using a cRNA probe,  Nuyt and 
co-workers (1999) found AGTR2 in the developing rat brain beginning at E11 in the 
lateral hypothalamic area and then increasing in expression and location throughout 
gestation and 28 days postnatally.   
A female patient with mental retardation and absence  AGTR2 gene expression 
was described previously (Vervoort et al. 2002).  A subsequent screening of 590 
unrelated patients with MR revealed one frame shift and three missense mutations in 
eight patients (Vervoort et al. 2002).   In a separate screening of 360 unrelated males 
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with non-syndromic X-linked mental retardation,  one patient was found to have a 
p.C117F change in the N-terminal domain of AGTR2 which was determined to be a 
rare polymorphic variant (Bienvenu et al. 2003).  A study of 57 similarly affected 
Finnish male patients found one patient with the G21V mutation and one with an 
I53F in the transmembrane domain (Ylisaukko-ojo et al. 2004).    However, Erdman 
and co-workers (2004) found in a screening of 631 males and 277 females, that 1 
male with dilated cardiomyopathy and another male with hypertrophic 
cardiomyopathy had the G21V mutation as well as 2 normal controls.  None of these 
patients had reported mental deficits.  Several proteins (Erb3, PLZF, ATIP, NHE6) 
have been found to interact with AGTR2 through in-vivo and in-vitro studies 
(Knowle et al. 2000; Senbonmatsu et al. 2003; Nouet et al. 2004; Pulakat et al. 2005).  
The sequence changes detected in patients with MR and the location known AGTR2 
interacting proteins are indicated in Figure P.2. 
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Figure P.2  Summary of mutations and interactions of AGTR2.  Mutations are in 
red, blue boxes are interacting proteins.  ECD=extra-cellular domain, ECL = Extra-
cellular loop, TMD = transmembrane domain, ICL = intracellular loop, ICD = 
intracellular domain. 
 
The AGTR2 gene is located at chromosome Xq23 in humans.   The gene is 4250 
bp long, consisting of 3 exons.  The entire open reading frame is contained in exon 3 
and transcribes a 2882 bp transcript.  The AGTR2 protein is a seven transmembrane 
receptor consisting of 363 amino acids of 41.2 kDa (Koike et al. 1994).  AGTR2 is 
highly expressed in fetal tissues with expression reducing rapidly after birth and then 
predominately only being expressed in the cerebellum, kidney, heart, adrenals, 
vasculature and pancreas (Berry et al. 2001). 
In the mouse, the Agtr2 gene is located on XA1.3.  The gene is 4539 bp long, 
consisting of 4 exons making a 3204 bp transcript.  The coding region has been 
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found in exons 3 and 4, and encodes a 363 amino acid protein with a 95% homology 
to the human receptor (Eppig and Bult  2005). 
 The first AGTR2 knock-out mouse models were described in 1995 (Hein et 
al. 1995; Ichiki et al. 1995).  These mice were viable and fertile.  The mutant males 
showed increased fear and a reduction in exploratory behavior and decreased body 
temperature, sensitivity to pain, startle response and drinking response.  Cell number 
in the brains of the Agtr2-/y mice was increased, but cell size was not affected (von 
Bohlen und Halbach et al. 2001)  Sakagawa and collaborators (2000) found that 
AGTR2 knockout mice had an increased sensitivity to pain and lower levels of brain 
β-endorphin.  
 Microarrays are used in Chapter 1 to elucidate the differences in gene 
expression in the brains of Agtr2-/y   versus normal embryonic day 15 (E15) and 
postnatal day one (P1) mice.  Our findings point to predicted and novel pathways for 
AGTR2 in brain development, as well as differences in its function at different 
points in development. 
In Chapter 2, the screening of a human fetal brain library with the N-terminal 
and C-terminal domains of AGTR2 utilizing a yeast two-hybrid system is discussed.  
The screening with the N-terminal domain found three novel interacting proteins:  
GNB2L1, (also known as RACK-1), NGLY1 and ASTML. 
In Chapter 3, angiotensin II interacting protein (ATIP) is partially 
characterized.  ATIP has previously been shown to interact with the C-terminal 
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intracellular domain of AGTR2 (Nouet et al. 2004; Wruck et al. 2005).   One isoform 
of the ATIP gene is characterized in the central nervous system.  A mutation screen 
of ATIP in patients with MR was undertaken, but no disease causing mutations were 
identified. 
 A female patient with an X;7 translocation and an absence of  AGTR2 gene 
expression (Vervoort et al. 2002), is discussed in the appendix.  This patient did not 
have a disrupted AGTR2 gene, so several molecular methods were employed to 
attempt to find a regulatory region for AGTR2. A deletion in the patient’s Xq22  
chromosome region was found.  This region contained a pseudogene for SUMO2 
was found,  which may contribute to the absent expression of AGTR2. Though the 
patient’s CUTL1 gene was disrupted on chromosome 7, the patient demonstrated 
expression of this gene.   
In summary, work in this dissertation includes identification of genes whose 
functions are likely influenced by AGTR2 in the developing brain.  Three proteins 
that interact with AGTR2 were identified and partially characterized in patients with 
AGTR2 defects.  A previously identified AGTR2 interacting protein, ATIP, was 
characterized and tested as a candidate gene for mental retardation.  Altogether, the 
results support a likely role of AGTR2 mediated signaling in brain development and 
function. 
 . 
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MICROARRAY ANALYSIS REVEALS GENES CONTRIBUTING TO 
ABNORMAL DENDRITIC SPINES IN AGTR2-/Y MOUSE 
 
 
 Mental retardation (MR) is the most common developmental disability, 
affecting cognitive function in about 1-3% of the human population.  Studies in 
humans and mice indicated a possible role for the angiotensin II type 2 receptor 
(AGTR2) in learning, memory and behavior.    However, AGTR2 gene function in 
the brain and the molecular mechanism by which AGTR2 exerts is physiological 
action remains elusive. 
The role of the renin-angiotensin system in blood pressure control and fluid 
homeostasis is well established.  Angiotensin II  binds to angiotensin II type one 
receptor  (AGTR1) and type 2 receptor (AGTR2) receptor.  Both receptors have 
been shown to have opposing physiological effects (Berry et al. 2001).  AGTR1 
affects vasoconstriction, cell proliferation, cell hypertrophy, superoxide production, 
endothelin release, lipid peroxidation, adhesion molecule expression and vascular 
matrix expression primarily through phospholipases C, D and A2 (Berry et al., 2001; 
(Csikos et al. 1998). The AGTR2 receptor has been shown to have a balancing effect 
to AGTR1 in regard to blood pressure and natriuresis (Berry et al. 2001). It has also 
been shown to inhibit growth and induce apoptosis (Yamada et al. 1996).  It also 
decreases cyclic guanosine monophosphate levels (GMP) and increases the 
production of arachidonic acid (Nahmias and Strosberg 1995).  AGTR2 activates 
serine/threonine protein phosphatase two A (PP2A),  the nitric oxide pathway as 
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well as phospholipase A2 which contribute to vasodilation through the upregulation 
of prostaglandins, bradykinin and nitric oxide (Berry et al. 2001).  The synthesis of 
ceramide also has been associated with stimulation of AGTR2 which in turn  induces 
apoptosis (Lehtonen et al. 1999; Berry et al. 2001). 
AGTR2 has also been shown to up-regulate the microtubule proteins 
polymerized β-tubulin and MAP2 in PC12W cells (Stroth et al. 1998).    It has also 
been demonstrated that stimulation of AGTR2 inhibits cell proliferation and induces 
neurite outgrowth (Meffert et al. 1996).    AGTR2 knockout mice showed an 
increase in cell number in the brain, especially in the ventral thalamic nuclei and 
medial nucleus of the amygdala that persists into adulthood (von Bohlen und 
Halbach et al. 2001). 
 Previous findings have shown that AGTR2 knockout mice were viable and 
fertile (Hein et al. 1995; Ichiki et al. 1995).  However, the behavior and learning 
abilities of AGTR2 knockout mice differ from normal mice.  AGTR2 knockout mice 
demonstrate a lowered pain threshold than normal mice (Sakagawa et al. 2000).  
These mice also show more anxiety type behaviors (Okuyama et al. 1999).  Mutant 
mice lacking the Agtr2 gene (Agtr2-/y ) were found to be significantly impaired in their 
learning performance and exhibited abnormal dendritic spine morphology (C. Maul, 
unpublished data), a feature consistently found to be associated with MR.  In a test 
of spatial memory, six month old AGTR2 knockout mice exhibited impaired 
performance in a maze and also demonstrated impaired learning in a one-way active 
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avoidance task (Maul unpublished data).  These mice also have a  decrease in 
spontaneous movement (Hein et al. 1995) and exploratory behavior (Ichiki et al. 
1995). 
Expression of AGTR2 has been shown to be ubiquitous in the fetus and 
then declines rapidly after birth (Grady et al. 1991).  Expression in the rat brain is 
detectable at embryonic day 13 (E13) and its expression changes in both intensity 
and locality in the brain throughout prenatal development and postnatally (Nuyt et 
al. 1999).   
In order to identify transcripts in the developing brain that depend on 
AGTR2 function, we analyzed RNA isolated from brains of Agtr2-/y and control mice 
at developmental stage E15 and at birth using Agilent Whole Mouse Genome 44K 
arrays. Gene expression profiles of the Agtr2-/y brain samples were compared to 
profiles of the control brains.  Furthermore, the expression profiling data generated 
in this study point to a role for AGTR2 that is likely independent of the renin-
angiotensin system.   
Methods 
Animals 
 Pre-dissected organs from animals were provided from Agtr2-/y  breeding 
stocks by Dr. T. Walther at the Charité, Campus Benjamin Franklin, Berlin, 
Germany.  These mice are from the 129/sv strain on a C57BL/6 x 129 mixed 
genetic background with a disrupted Agtr2 gene.   
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Genotyping of animals was performed after isolating DNA from liver. PCR 
was performed with the following primer sets: knockout- NeoPvu-F – 5’ 
GGCAGCGCGGCTATCGTGG 3’ and control – AT25 (F) 5’ CCACCAGCAGA-
AACATTACC 3’ and the same reverse primer was used for both: AT23 (R) 5’ GAA-
CTACATAAGATGCTTGCCAGG 3’. (Primer sequences provided by T. Walther) 
The following conditions were used for amplification: 95ºC for 5 min., 95ºC for 30 
sec., 60ºC for 30 sec., 72ºC for 45 sec. for 30 cycles followed by 72ºC for 7 min.  Sex 
was determined by genotyping with an X-linked gene Jarid1 C, using the following 
primers:  Forward 5’ CTGAAGCTTTTGGCTTTGAG 3’ and reverse – 5’ 
CCACTGCC-AAATTCTTTGG 3’ with the following conditions: 95ºC for 5 min., 
95ºC for 20 sec., 56ºC for 30 sec., 72ºC for 40 sec. for 30 cycles followed by 72ºC for 
7 min. (Clapcote and Roder 2005)  Jarid1 C primers will produce a 331 bp and 302 
bp band in males and a single 331 bp band in females, as there is a homologue to 
Jarid1 C on the Y chromosome (Figure 1.1). 
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Figure 1.1  Agarose gel of Jarid1C PCR of E15 Agtr2-/y  mouse DNA.  Males have a 
331 bp and 302 bp band and females have a 331bp band.  Control female is indicated 
by the arrow. 
 
RNA extraction   
Total RNA was extracted from frozen slices of whole brain weighing less 
than 30µg using the Qiagen RNeasy kit (Qiagen) according to manufacturer 
instructions.  Samples were cleaned with DNase using the Ambion Turbo DNase-
free kit (Ambion Inc.).  RNA samples were analyzed on the Agilent 2100 expert 
bioanalyzer (Agilent) for purity and concentration.   Two microliters of purified 
RNA were loaded on a RNA 6000 Nano LabChip (Agilent) along with 2 µl of RNA 
ladder (Ambion) and fluorescent marker from the Nano LabChip kit.  The chip was 
read by the Agilent 2100 Bioanalyzer.  The bioanalyzer software computed sample 
concentration, ratio of 18S  to 28S ribosomal RNA and produced a gel image and 
electropherogram. 
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Microarray hybridization 
RNA from 6 male controls and 8 male knockouts at stage E15 was amplified 
individually and labeled with the Agilent low RNA Input Linear Amplification Kit  
(Agilent) according to manufacturer instructions.  In brief, cDNA was synthesized 
using a T7 primer and was then labeled with Cy3- or Cy5-CTP.  Samples were 
purified with Qiagen RNasey mini spin columns (Qiagen).   Equal amounts of  
control sample and Agtr2-/y  sample were labeled with Cy3 or Cy5 respectively and 
were hybridized to the first set of 8 Agilent Whole Mouse Genome Oligo 44K 
Microarrays slides (Agilent)  according to the Agilent protocol.  On the second set of 
microarray slides, the control samples were paired with a different knockout sample. 
The experimental strategy is outlined in figure 1.2.  Arrays were hybridized for 17 
hours at 65ºC and then washed with 6X SSC, 0.005% Triton X-102 for one minute 
and then with 0.1X SSC, 0.005% Triton X-102 for one minute and then for 30 
seconds in ozone scavenging solution (Agilent #5185-5979) .  The microarray slides 
were scanned on an Agilent microarray scanner and data was normalized and 
extracted with Feature Extraction 8.0 software (Agilent).  RNA from 4 male control 
and 4  P1 Agtr2 -/y  brains was handled in the same fashion, with all controls being 
dye-swapped with a different knockout in each dye selection (Figure 1.2). 
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Figure 1.2  Experimental design  for E15 and P1 mouse brains on Agilent Whole 
Mouse Genome 44K expression arrays demonstrating dye-swap strategy.  K = 
 Agtr2-/y  samples, C = control samples.   
 
Data analysis 
Normalized data from each array were reviewed to determine hybridization 
efficiency.  Two arrays were not included due to poor hybridization.  A list of over 
and under expressed genes for each developmental stage was generated using a 
Student’s t-test with a Benjamini and Hochberg false discovery rate (Benjamini 2000) 
statistic using both GeneSpring GX (Agilent) and Bioconductor marray and limma  
software (Smyth 2005; Team 2005; Yee 2005).  A list was produced using 
GeneSpring GX© using a p≤ 0.001 and a FDR ≤ 0.3  for stage E15 of 88 up-
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regulated and 45 down-regulated genes.  Ninety-five genes had on-chip replicates 
and 5,996 genes had insufficient data for a comparison.  Also using GeneSpring GX  
with a p ≤ .005 and a FDR ≤ .3, for the newborn stage, a list of 270 up-regulated 
and 127 down-regulated genes was produced.   There were 2971 genes that had 
insufficient data for comparison. Using the R statistical language (Team 2005)  
Bioconductor with the marray (Yee 2005) and limma (Smyth 2005) packages were  
implemented to provide a second analysis.  The p-values with a Benjamini and 
Hochberg false discovery rate and the fold change using a log2 transformation of all 
genes on all arrays were calculated using limma.   A summary of the creation of the 
final lists is seen in Figures 1.3a and 1.3b.  Annotation of genes in the list were 
enhanced buy using the DAVID Gene Id Conversion Tool (Dennis et al. 2003). 
Hierarchical clustering (condition tree) of the embryo arrays was performed 
by GeneSpring GX using a Pearson correlation with a clustering algorithm = average 
linkage, with a separation ratio of 1 and a minimum distance of 0.001 using the E15 
final list.  Clustering of the P1 arrays (gene tree) was performed in the same way 
using a Pearson correlation with a clustering algorithm = average linkage, discarding 
genes with no data in half the starting conditions and bootstrapping 100 sets.  Gene 
tree clustering on the entire embryo set was not possible due to computing 
limitations. 
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Figure 1.3a  Flow chart of creation of E15 final list.  Normalized data was analyzed 
with GeneSpring GX and Bioconductor Limma to add strength to the results. 
 
 
Figure 1.3b  Flow chart of creation of P1 final list.  Normalized data was analyzed 
with GeneSpring GX and Bioconductor Limma to add strength to the results. 
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Quantitative PCR 
RNA was isolated as previously described on 4 controls and 4 knockouts 
from each developmental stage, and from mice other than ones used in the 
microarray experiment previously.  Primers were designed using the Primer3 
program (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi) (Rozen and 
Skaletsky 2000).  Biorad I-Script 1 step RT-PCR with SYBR green (Biorad) was used 
according to manufacturer instructions with 5 ng of RNA per sample used.  Samples 
were run in triplicate on a Biorad i-cycler and analyzed using a standard curve 
method  (Larionov et al. 2005)A control gene, AK029535 (Riken cDNA493050c13)  
was selected from a list of genes showing the least difference in expression generated 
by limma using the  model 1a algorithm  as described by Szabo et. al (Szabo et al. 
2004).   The list of primers used is in Table1.1. 
 
Table 1.1 
Primers for Quantitative RT-PCR of E15 and P1 Mouse Brains 
  
Primer 
Name 
Genebank 
Accession 
Annealing 
Temperature 
ºC 
Sequence 5’ – 3’ 
Product 
Size 
(bp) 
AK029535 AK029535 55 F-GACAGTGGAGGGGAGAATGA 
R -ACCGAGTTCTGGGTGTTGAC 240 
Prdm16 NM_027504 63 F-AGGGCAAGAACCATTACACG R-AGAGGTGGTCGTGGGTACAG 247 
Bmp2kb NM_080708 60 F-CATTTCCGATTCCAAGGAGA R-GGAAGGACCCGTGTACTGAA 224 
Pisd AK005333 61 F-GGAGCAGTGACCACACTGAA R-ACATCTTGCGTAGGCACAGG 150 
013803 AK013803 53 F-TGGCTCTCTTCCTGATTGGT R-CCAAACAAGGGTCTTCCAAA 190 
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Table 1.1 (continued) 
 
Prosc BC047992 64 F-AGGGTGTGGTGAGGATTCTG R-GACGAGAACTGTGCACCTGA 209 
C77370 XM_205178 57 F-GCAGGACTTGCTTAGGTTGC R-TTGACTTATGCAGGGGGAAG 210 
050558 AK050558 64 F-TCTTTCCCGAGTTCTGCTGT R-GGGAACAACCAGGCTCATAA 225 
Syn2 NM_013681 57 F-ATGGCAAAGATGGCAAAGAC R-CCGGTTCCTTAAGTGTTCCA 204 
Mtap2 AK086484 55 F-CTGGACATCAGCCTCACTCA R-AATAGGTGCCCTGTGACCTG 164 
Casc4 
 NM_177054 55 
F-GAAGCAGATCGACCAGAAGG 
R-TTCTAGCCGCTTGACAAGGT 163 
Prie4 AK009137 56 F-TGTAACTGGGCTCCTTGCTT R-TTGCAAAGACCTCTCCTGGT 195 
Ube2m NM_145578 61 F-CGACCTCCTCAACTTCAAGC R-CTGGCTTCCAGTCCTCTCTG 200 
Gnb2l1 NM_008143 55 F-GCAAGTACACGGTCCAGGAT R-GGGATCCATCTGGAGAGACA 204 
Achy L32836 50 F-CGTGATGAGCAACTCCTTCA R-TGGTCAGCTTCACATTCAGC 155 
Gls AK047664 65 F-TCAGTGCCCTTAATTGCTGA R-CTTGCATAGGTCACGGGTTT 249 
Rbm26 NM_134077 55 F-CTCCACTTCCTCCTTTGCAG R-CTTGGGGCTTCAGGATTGTA 187 
Add1 AK031960 62 F-TCCTTCCCTTTTGGCTTTTT R-ACCCTCTTCCCGAGTAAGGA 192 
S3fb AK017529 62 F-TCCGTTTGTTTTGGTGTTGA R-TACAAGGCTGTCACGGATGA 236 
Chuk NM_007700 61 F-TGGAGCCTACGAAGCTGTTT R-CCCTCATTAGTTGCGGTGTT 234 
Gpi AK051363 56 F-ATGAACAGGCCTTCAGCATT R-AAAGCCTTGCTCCCTACACA 215 
Atp6 AF093677 55 F-CCTTCCACAAGGAACTCCAA R-GGTAGCTGTTGGTGGGCTAA 187 
Pp2cb NM_017374 53 F-CTATCCAGAGCGCATCACAA R-TCCAGGGCTCTTATGTGGTC 234 
Frg1 NM_013522 60 F-GGGAGCTCCACACAGAGAAG R-GCCATCTTCCCATCTTGAAA 204 
Nasp NM_016777 60 F-TGGCTGTACTCCATGAGCAG R-TCATGGATACTGAGGCACCA 228 
At2b NM_007429 55 F-AGCAGCCGTCCTTTTGATAA R-TGCTGGACACCTTTTTAGGG 196 
Ace NM_207624 61 F-CAGTGTCTACCCCCAAGCAT R-TTCCATCAAAGACCCTCCAG 165 
Agtr1a NM_177322 57 F-GGAAACAGCTTGGTGGTGAT R-TGAGACACGTGAGCAGGAAC 235 
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Table 1.1 (continued) 
 
Agt NM_007428 57 F-CACCCCTGCTACAGTCCATT R-GTCTGTACTGACCCCCTCCA 221 
 
Results 
Gene expression profiles of the Agtr2-/y brain samples were compared to 
profiles of the control brains for two developmental stages, E15 and at birth (P1).  
The graphed log ratios by dye swap are presented in Figures 1.4 and 1.5.  
Hierarchical clustering of each developmental set demonstrated that the Agtr2-/y  
mouse brains had an overall different expression pattern than did those of controls, 
as controls and Agtr2-/y samples clustered separately and are shown in Figure 1.6.   
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Figure 1.4  Log ratios of all embryo (E15) arrays by dye-swap.  X axis = knockouts 
labeled blue, controls red; Y axis = knockouts labeled red, controls blue. 
 
 
 Figure 1.5  Log ratios of  all postnatal day one (P1) by dye-swap.  X axis = 
knockouts labeled blue, controls labeled red;  Y ax is = knockouts labeled red, 
controls blue. 
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                          A                                                                    B 
Figure 1.6   Hierarchal clustering showing knockout animals have different 
expression profiles as represented by the dye swap color coding below the tree. A) 
embryo (E15) arrays B) postnatal day one (P1) arrays.   
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Data analysis using GeneSpring GX© (FDR ≤ 0.3 and p ≤ 0.001) produced a 
list of 133 genes (88 up-regulated, 45 down-regulated) differentially expressed at E15. 
A similar analysis (FDR ≤ 0.3 and p≤ 0.005) in newborn brains identified a list of 
397 differentially expressed genes (270 up-regulated, 127 down-regulated) in Agtr2-/y 
mouse brains. To further narrow the gene lists, genes that had a fold change greater 
than or equal to 1.3 and a p-value less than 0.001 in the E15 were selected (Figure 
1.3a).  This resulted in a list of 62 genes (52 up-regulated and 10 down-regulated) for 
the E15 brains (Table 1 .2 and Figure 1.7 and 1.8).   In the P1 samples, a fold change 
greater than or equal to 1.4 and p-value less than 0.005 was selected for a final list 
(Figure 1.3b).  This resulted in a list of 62 genes (50 up-regulated and 12 down-
regulated) in the neonates (Table 1.3 and Figure 1.9 and 1.10).   Fold change was 
computed with Bioconductor software with a log2 transformation.  The final E15 
and P1 lists had AK005333 (phosphatidyl decarboxylase) and AK084084 (Rab30) in 
common.  AK005003 was up-regulated 1.6 fold (p = 1.08E-04) in the E15 and 1.9 
fold (p = 3.39E-04) in the P1, while AK084084 was up-regulated 1.5 fold (p = 
6.86E-04) in the E15 brains and 1.7 (p = 1.22E-04) in the P1.  The E15 list had two 
genes listed twice with two separate probes:  NM_177054 (Casc4) and NM_033563 
(Klf7).   
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Figure 1.7  Tile view of final list of up-regulated genes in Agtr2-/y  E15 brains.  Each 
row is an individual array KO red = arrays with Agtr2-/y samples labeled red,  KO 
blue = arrays with Agtr2-/y samples labeled blue.  Expression is represented as a 
gradient from red to blue, red being the highest expression and blue being the 
lowest.  Each column represents an individual gene spot.  Gene names are listed 
below each column.  
 
 
Figure 1.8  Tile view of final list of down-regulated genes in Agtr2-/y  E15 brains.  
Each row is an individual array KO red = arrays with Agtr2-/y samples labeled red,  
KO blue = arrays with Agtr2-/y samples labeled blue.  Expression is represented as a 
gradient from red to blue, red being the highest expression and blue being the 
lowest.  Each column represents an individual gene spot.  Gene names are listed 
below each column.  
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Table 1.2 
Genes at Day E15 Showing Fold Change ≥ 1.3 and p < .001 in Agtr2-/y Brains 
 
Probe set Genebank 
Gene 
Symbol 
Gene Name P value 
Fold 
Change
A_51_P514139 NM_027504 Prdm16 PR domain containing 16 1.97E-04 +3.1 
A_52_P546610 NM_013626 Pam 
peptidylglycine alpha-
amidating 
monooxygenase 
6.72E-05 +2.1 
A_51_P337944 NM_080708 Bmp2k BMP2 inducible kinase 7.96E-07 +1.9 
A_52_P561377 NM_145505 AI450540 expressed sequence AI450540 1.88E-05 +1.9 
A_52_P542860 NM_172618 Btbd9 BTB (POZ) domain containing 9 1.61E-03 +1.8 
A_52_P135424 AK032599   1.45E-03 +1.6 
A_52_P654624 AK005333; Pisd phosphatidyl decarboxlyase 1.08E-04 +1.6 
A_52_P342836 BC055351 AY358078  2.83E-03 +1.6 
A_52_P150396 AK013803; male hippocampus
RIKEN cDNA 
2700059D21 gene 9.00E-05 +1.6 
A_52_P54666 AK086484; Mtap2 microtubule associated protein2 4.68E-04 +1.6 
A_52_P188425 BC047992; Prosc proline synthetase co-transcribed 5.66E-04 +1.5 
A_51_P247114 NM_008199 H2-BL histocompatibility 2, blastocyst 8.23E-06 +1.5 
A_52_P617386 AK084084 Rab 30  6.86E-04 +1.5 
A_51_P393161 AK049497 Zfp291  1.33E-04 +1.5 
A_51_P496779 NM_194462 Akap9 A kinase (PRKA) anchor protein (yotiao) 9 1.40E-04 +1.5 
A_51_P446575 AK044903; Fnbp1l Formin binding protein 1-like 2.56E-04 +1.4 
A_52_P207132 AK044972; Plcxd3 
phosphatidylinositol-
specific phospholipase 
C, X domain containing 
3 
5.10E-04 +1.4 
A_52_P462472 XM_205178 C77370 expressed sequence C77370 9.91E-05 +1.4 
A_52_P110581 AK050558; pancreas islet cells cDNA 
RIKEN cDNA 
A930011G23 gene 1.13E-04 +1.4 
A_51_P212515 NM_178726 Ppm1l protein phosphatase 1 (formerly 2C)-like 1.55E-03 +1.4 
A_51_P227866 AK030696 Txndc13 Thioredoxin domain containing 13 2.31E-04 +1.4 
A_52_P503135 NM_177054 Casc4 RIKEN cDNA D130060C09 gene 1.47E-03 +1.4 
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Table 1.2 (continued) 
 
A_52_P90101 AK036209; Atxn2 spinocerebellar ataxia 2 homolog (human) 1.85E-03 +1.4 
A_51_P172241 TC1312974   4.07E-05 +1.4 
A_52_P660753 XM_194622 Taf1 
TAF1 RNA poly II 
TATA box binding 
protein 
8.54E-04 +1.4 
A_52_P239424 AK086122 Klf7 Kruppel-like factor 7 (ubiquitous) 8.96E-04 +1.4 
A_52_P424197 AK029131 AI585793  4.43E-04 +1.4 
A_51_P366277 BC049166 Nol8  1.14E-03 +1.4 
A_52_P16346 AK012005; Sla2 SRC like adaptor 2 1.93E-04 +1.4 
A_52_P268720 BC021818 Helz  2.30E-04 +1.4 
A_51_P134801 XM_619483 Ankrd12 Ankyrin repeat domain 12 2.95E-04 +1.4 
A_51_P308628 XM_619630 Nbeal Neurobeachin like 1 1.07E-03 +1.4 
A_51_P128075 NM_027028 Ca binding riken gene 
RIKEN cDNA 
1700008P20 gene 1.16E-03 +1.4 
A_52_P407755 AK009137; Prei4 Preimplantation protein 4 1.14E-03 +1.4 
A_51_P512340 NM_019840 Pde4b phosphodiesterase 4B, cAMP specific 1.35E-04 +1.3 
A_51_P364894 NM_054089 Ncoa6ip 
nuclear receptor 
coactivator 6 interacting 
protein 
2.90E-03 +1.3 
A_52_P462171 XM_354675 Arid4a AT rich interactive domain 4A (Rbp1 like) 6.96E-04 +1.3 
A_51_P217878 AK043468; Mtap1b microtubule associated protein 1B 3.78E-04 +1.3 
A_52_P167166 AK047842; Shprh  4.26E-04 +1.3 
A_52_P540045 AK083897; Dgkh Diacylglycerol kinase, ETA 1.39E-03 +1.3 
A_52_P289071 NM_177054 Casc4 cancer susceptibility candidate 4 5.10E-04 +1.3 
A_51_P115940 NM_172787 L3mbtl3 l(3)mbt-like 3 (Drosophila) 3.44E-04 +1.3 
A_52_P5549 NM_026583 discontinued record 
RIKEN cDNA 
5830415L20 gene 1.11E-04 +1.3 
A_52_P38317 AK046153; Nat5 
N-acetyltransferase 5 
(ARD1 homolog, S. 
cerevisiae) 
1.36E-03 +1.3 
A_51_P127215 BC003348; Sesn3 sestrin 3 3.77E-03 +1.3 
A_51_P405280 NM_033563 Klf7 Kruppel-like factor 7 (ubiquitous) 5.19E-04 +1.3 
A_52_P190807 AK032690   9.75E-04 +1.3 
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Table 1.2 (continued) 
 
A_52_P519538 NM_172712 Ube1l2 RIKEN cDNA 5730469D23 gene 1.11E-04 +1.3 
A_52_P197199 XM_139187 Pcdh9 protocadherin 9 2.01E-04 +1.3 
A_52_P521507 BC051169 Trio Trio 5.54E-04 +1.3 
A_52_P621817 AK173240 Zfp46  2.49E-04 +1.3 
A_52_P651784 XM_486486 discontinued record 
similar to S-
adenosylmethionine 
decarboxylase 
1.15E-04 +1.3 
A_51_P349008 NM_133783 Ptges2 prostaglandin E synthase 2 3.86E-04 -1.3 
A_51_P218805 NM_212443 Gfer 
growth factor, erv1 (S. 
cerevisiae)-like 
(augmenter of liver 
regeneration) 
9.44E-04 -1.3 
A_52_P108808 TC1316888 TC1316888  5.85E-04 -1.3 
A_52_P20639 NM_023727 hypoth. Protein 
RIKEN cDNA 
3322402L07 gene 2.41E-04 -1.3 
A_51_P506937 NM_011885 Mrps12 mitochondrial ribosomal protein S12 5.48E-04 -1.3 
A_51_P432538 NM_010395 H2-t10 histocompatibility 2, T region locus 10 5.17E-04 -1.3 
A_51_P344566 NM_011121 Plk1 polo-like kinase 1 (Drosophila) 2.81E-05 -1.4 
A_51_P272172 NM_053068 Chrac1 chromatin accessibility complex 1 3.74E-04 -1.4 
A_51_P100246 NM_145578 Ube2m ubiquitin-conjugating enzyme E2M 1.00E-03 -1.4 
A_51_P288549 BC016255 Pla2g4b phospholipase A2, group IVB (cytosolic) 1.54E-05 -1.7 
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Figure 1.9  Tile view of final list of up-regulated genes in Agtr2-/y  P1 brains.  Each 
row is an individual array KO red = arrays with Agtr2-/y samples labeled red,  KO 
blue = arrays with Agtr2-/y samples labeled blue.  Expression is represented as a 
gradient from red to blue, red being the highest expression and blue being the 
lowest.  Each column represents an individual gene spot.  Gene names are listed 
below each column.  
 
Figure 1.10   Tile view of final list of down-regulated genes in Agtr2-/y  P1 brains.  
Each row is an individual array KO red = arrays with Agtr2-/y samples labeled red,  
KO blue = arrays with Agtr2-/y samples labeled blue.  Expression is represented as a 
gradient from red to blue, red being the highest expression and blue being the 
lowest.  Each column represents an individual gene spot.  Gene names are listed 
below each column.  
  31                         
Table 1.3 
Genes at P1 Showing Fold Change ≥ 1.4 and p < .005 in Agtr2-/y Brains 
 
Probe Set Genebank Gene Symbol Gene Name P Value 
Fold 
Change 
A_51_P222953 AK047664 Gls  8.890E-06 +2.2 
A_52_P329105 NM_134077 1700009P03Rik 
RIKEN cDNA 
1700009P03 gene 4.510E-03 +2.1 
A_52_P386075 XM_622182   1.040E-03 +2.1 
A_51_P304449 AK031960 Add1  1.270E-04 +2.0 
A_51_P390755 AK035845 Ptprs RIKEN cDNA 9630010G10 gene 1.380E-04 +2.0 
A_52_P654624 AK005333 Pisd RIKEN cDNA 4933439C20 gene 3.390E-04 +1.9 
A_52_P657817 AK030767 Mapk8 mitogen activated protein kinase 8 5.090E-04 +1.9 
A_52_P368881 TC1323355   3.770E-04 +1.9 
A_52_P102630 AB063319 Rian  4.280E-04 +1.8 
A_52_P320822 NM_177199 Sfrs10 RIKEN cDNA 5730405G21 gene 7.950E-04 +1.8 
A_52_P236097 AK017529 Sf3b3 splicing factor 3b, subunit 3 7.340E-04 +1.8 
A_52_P92213 AK089867   8.570E-04 +1.7 
A_52_P386468 NM_007700 Chuk 
conserved helix-
loop-helix 
ubiquitous kinase 
2.200E-06 +1.7 
A_52_P475033 AK088515   9.930E-04 +1.7 
A_52_P617386 AK084084 Rab 30  1.220E-04 +1.7 
A_52_P422088 AK084846 Ptbp2 PTBP2 5.190E-04 +1.7 
A_52_P440027 AK014565 4632411B12Rik 
RIKEN cDNA 
4632411B12 gene 9.200E-04 +1.6 
A_52_P24835 NM_027893 Pvrl4 poliovirus receptor-related 4 5.330E-04 +1.6 
A_52_P484519 AK171368 Sept 11  8.820E-04 +1.6 
A_52_P319752 AK046219 Nudcd3 NudC domain containing 3 4.860E-04 +1.6 
A_52_P527329 AK089867   8.570E-04 +1.6 
A_51_P183154 AK049897 Hook1  6.280E-04 +1.6 
A_52_P955951 AK048907 Gria4  2.170E-04 +1.6 
A_52_P340618 BC030361 Eml5 
echinoderm 
microtubule 
associated protein 
like 5 
7.360E-04 +1.6 
A_52_P323215 NM_019570 Rev1l REV1-like (S. cerevisiae) 3.080E-05 +1.6 
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A_52_P433 AK129392   5.040E-04 +1.6 
A_52_P671465 AK051363 Gpiap1  2.720E-04 +1.6 
A_51_P458230 AK054427   8.970E-04 +1.6 
A_52_P276412 AK011886 Atpif1  6.450E-04 +1.6 
A_52_P620432 AK019968 2410005O16Rik 
RIKEN cDNA 
2410005O16 gene 6.000E-04 +1.6 
A_52_P398494 XM_902635 Ankrd11  7.040E-04 +1.5 
A_52_P113585 AK084575 Hdh HDH 1.000E-04 +1.5 
A_52_P411015 NM_177300 B130040O20Rik 
RIKEN cDNA 
B130040O20 gene 6.150E-04 +1.5 
A_52_P61903 AK014174 Chka choline kinase alpha 4.240E-04 +1.5 
A_52_P182520 BC028435 Timm9  3.110E-04 +1.5 
A_52_P668157 AK011905 Ncam1  8.800E-05 +1.5 
A_52_P124105 AK083451 Rab14 
RAB14, member 
RAS oncogene 
family 
1.110E-04 +1.5 
A_52_P98160 TC268598   5.940E-04 +1.5 
A_52_P188026 BC051052 Ccar1 CCAR 3.710E-04 +1.5 
A_52_P59544 AK036220 Rbm18  3.110E-04 +1.5 
A_52_P72938 AK039096 AI790442 expressed sequence AI790442 8.760E-04 +1.5 
A_52_P321318 AF093677 mt-Atp6 ATP synthase 6, mitochondrial 3.140E-04 +1.5 
A_52_P236607 BC066170 Ercc8 
excision repaiross-
complementing 
rodent repair 
deficiency, 
complementation 
group 8 
3.100E-04 +1.4 
A_52_P289213 BC059256 Notch2 Notch2 8.250E-04 +1.4 
A_52_P454703 BE650851   3.580E-04 +1.4 
A_51_P358256 NM_009803 Nr1i3 
nuclear receptor 
subfamily 1, group 
I, member 3 
6.810E-04 +1.4 
A_52_P171993 AK012463 Psmd7 
proteasome 
(prosome, 
macropain) 26S 
subunit, non-
ATPase, 7 
7.320E-04 +1.4 
A_52_P146848 NM_016690 Hnrpdl 
heterogeneous 
nuclear 
ribonucleoprotein 
D-like 
2.740E-04 +1.4 
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A_52_P237755 TC1517524   8.580E-04 +1.4 
A_52_P860487 ac1158020   6.740E-04 +1.4 
A_51_P122246 NM_029720 Creld2 RIKEN cDNA 5730592L21 gene 3.360E-04 -1.4 
A_51_P281255 NM_016777 Nasp 
nuclear 
autoantigenic sperm 
protein (histone-
binding) 
1.840E-04 -1.4 
A_52_P576863 NM_025922 Itpa 
inosine 
triphosphatase 
(nucleoside 
triphosphate 
pyrophosphatase) 
8.830E-04 -1.4 
A_51_P259001 NM_029814 Chmp5 RIKEN cDNA 2210412K09 gene 3.150E-04 -1.4 
A_52_P476357 NM_016878 Dnpep aspartyl aminopeptidase 8.290E-04 -1.4 
A_52_P141786 NM_029561 Ndfip2 Nedd4 family interacting protein 2 3.940E-04 -1.4 
A_51_P349142 NM_007991 Fbl fibrillarin 1.640E-04 -1.4 
A_51_P479802 XM_110248 Fbxo11 F-box protein 11 2.630E-05 -1.4 
A_51_P125535 NM_017374 Ppp2cb 
protein phosphatase 
2a, catalytic subunit, 
beta isoform 
5.120E-04 -1.6 
A_51_P132978 NM_010497 Idh1 
isocitrate 
dehydrogenase 1 
(NADP+), soluble 
7.520E-04 -1.6 
A_51_P117226 AK046533   1.020E-04 -1.6 
A_51_P267544 NM_013522 Frg1 FSHD region gene 1 6.180E-04 -1.6 
 
Randomly selected genes from each list (Table 1.1) were validated by 
quantitative RT-PCR.  In the majority of cases the fold change levels found by RT-
PCR correlated well with the expression profile array data (Tables 1.4 and 1.5).  
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Table 1.4 
RT-PCR Results of Selected Genes at E15 
 
Probe ID Primary Accession Gene Name FC RT-PCR FC 
a_51_P514139 NM_027504 Prdm16 3.1 1.3 
a_51_P337944 NM_080708 Bmp2 inducible kinase 1.9 1.4 
a_52_P654624 AK005333 Pisd 1.6 2.3 
a_52_P150396 AK013803 RIKEN CDNA 2700059D21 GENE 1.6 no change 
a_52_P188425 BC047992 proline synthestase 1.5 1.1 
a_52_P462472 XM_205178 expressed seq. C77370 1.4 no change 
a_52_P110581 AK050558 
RIKEN CDNA 
A930011G23 
GENE 
1.4 no change 
a_51_P396325 NM_013681 synapsin 2 1.3 1.3 
A_52_P54666 AK086484 Mtap2 1.6 1.3 
a_52_P503135 
a_52_P289071 NM_177054 Casc4 1.4 1.2 
a_52_P407755 AK009137 Prei4 1.4 1.7 
a_51_P100246 NM_145578 Ube2m -1.4 -1.2 
a_51_P488673 
a_52_P404108 
 
NM_008143 Gnb2L1 -1.3 -1.2 -1.5 
a_51_P473533 L32836 Ahcy -1.2 -1.7 
 
Table 1.5 
RT-PCR Results of Selected Genes at Postnatal Day 1 
 
Primary Accession Gene Name Probe ID FC RT-PCR FC 
AK047664 Glutaminase a_51_P222953 2.2 1.4 
NM_134077 Rbm26 a_52_P329105 2.1 1.3 
AK031960 Adducin 1 (alpha) a_51_P304449 2 1.7 
AK005333 Pisd a_52_P654624 1.9 1.7 
AK017529 splicing factor 3b a_52_P236097 1.8 1.4 
NM_007700 Conserved helix loop helix a_52_P386468 1.7 1.4 
AK051363 Gpi-anchored membrane protein 1 a_52_P671465 1.6 1.7 
AF093677 ATP synthase 6 a_52_P321317 1.5 no change 
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Table 1.5 (continued) 
 
NM_008143 Gnb2L1 
a_51_P488673 
a_52_P404108 
 
1.0 
-1.0 No change 
NM_017374 Protein phosphastase2cb a_51_P125535 -1.6 -1.4 
NM_013522 Frg1 a_51_P267544 -1.6 -1.7 
NM_016777 Nasp a_51_P281255 -1.4 -1.3 
 
The expression of genes involved in the renin-angiotensin pathway was also 
examined by RT-PCR and microarray values.  No significant differences were found 
for these genes at either time point on the arrays (Table 1.6). 
 
Table 1.6 
Comparison of E15 and P1 Values of Renin-Angiotensin System Genes 
 
Gene spotnumber 
E15 
RT-p-
value 
E15 
Array 
pvalue 
E15 
Array 
fold 
chg 
P1 
RT 
P-
value 
P1 array 
pvalue 
P1 Array 
foldchange 
Agtr2 A51P437978 .1 0.92 0.9 .04 0.741 1.23 
Agtr1 A51P236439 .84 0.92 0.97 .32 0.85 0.94 
 A52P645862 0.79 1.08 0.99 0.98 
Agtr1b A52P53617 0.86 1.03 0.98 0.98 
Ace A52P72297 .65 0.88 1.03 .16 0.91 0.95 
 A51P310523 0.93 1.06 0.95 1.07 
 A52P68028 0.84 0.95 0.94 0.94 
Agtrl1 A52P97572 0.71 0.89 .32 0.99 1.01 
 A51P299055 0.98 1 0.92 1.04 
Agtrap A52P330667 0.73 0.94 0.96 1.03 
 A51P271208 0.76 1.06 0.81 1.08 
 A52P552550 0.95 0.98 0.92 0.97 
 A52P480709 0.98 1.01 0.81 1.11 
Ace2 A51P257496 0.93 1.02 0.936 0.97 
Ren1 A52P652885 0.84 1.04 0.96 0.96 
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Table 1.6 (continued) 
 
 A52P544060 0.86 0.96 0.95 0.96 
 A51P316661 0.57 1.2 0.98 1.02 
Renbp A51P123765 0.44 0.88 0.99994 1 
Agt A51P323712 .37 0.92 1.02 .51 0.988 1.06 
 A51P436690 0.94 0.98 0.96 0.96 
 
A list of 388 genes was also produced that were found NOT to be expressed 
at either time point (data not shown).  Data analysis also revealed that there were 694 
genes with no expression in the embryos and 862 genes not expressed in the P1 (data 
not shown).  These genes were involved in a variety of physiological processes 
and/or cDNAs from adult tissues.  
To create a list of genes that were significantly differentially expressed at 
both developmental stages and to investigate which genes expression was affected by 
developmental stage, a two way ANOVA analysis was performed.  This analysis used 
developmental age and absence of Agtr2 as parameters and a Benjamini and 
Hochberg false discovery rate of 0.05.  This created a list of 118 (87 up and 31 down) 
differentially regulated genes in all knockouts and 3 (2 up and 1 down in neonates) 
differentially regulated genes for developmental stage (table 1.8).      The list of 
differentially regulated genes in all Agtr2-/y  mouse brains was compressed to 82 
genes, by eliminating genes with less than a 1.3 fold change (Table 1.7).  This list had 
15 genes in common with the E15 t-test list and 16 genes in common with the P1 t-
test list. 
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Table 1.7 
Significantly differentially regulated genes in Agtr2-/y ANOVA FDR=.05, 
fold change ≥ 1.3 
 
Probe Genebank 
Gene 
symbol 
Common Name FC 
A_52_P386075 AK004071   +1.9 
A_52_P654624 AK005333; 4933439C20Rik RIKEN cDNA 4933439C20 gene +1.7 
A_52_P561377 NM_145505 AI450540 expressed sequence AI450540 +1.7 
A_52_P381009 AK009502; Tia1 cytotoxic granule-associated RNA binding protein 1 +1.7 
A_52_P82704 AK122557 Bcl11a Mus musculus mRNA for mKIAA1809 protein +1.7 
A_52_P617386 AK084084 Rab 30  +1.6 
A_52_P368881 TC1323355   +1.6 
A_51_P222953 AK047664;   +1.6 
A_52_P54666 AK086484;   +1.6 
A_51_P337944 NM_080708 Bmp2k BMP2 inducible kinase +1.6 
A_52_P564625 TC1362404   +1.6 
A_52_P135424 AK032599   +1.6 
A_51_P247114 NM_008199 H2-Bl histocompatibility 2, blastocyst +1.6 
A_52_P150396 AK013803; 2700059D21Rik RIKEN cDNA 2700059D21 gene +1.5 
A_52_P236097 AK017529; Sf3b3 splicing factor 3b, subunit 3 +1.5 
A_51_P136820 NM_011179 Psap Prosaposin +1.5 
A_52_P504460 AK013634; Ccnt2 cyclin T2 +1.5 
A_51_P154668 NM_001004146 MGC65558 
similar to phosphatidylserine 
decarboxylase +1.5 
A_52_P372843 AK005295;   +1.5 
A_52_P320822 NM_177199 5730405G21Rik RIKEN cDNA 5730405G21 gene +1.5 
A_52_P280448 TC1254974   +1.5 
A_52_P342836 BC055351 AY358078  +1.5 
A_51_P183154 AK049897 Hook1  +1.5 
A_52_P422088 AK084846; Ptbp2  +1.4 
A_52_P4148 BC056964   +1.4 
A_52_P167166 AK047842;   +1.4 
A_52_P623457 NM_178922 Hic2 hypermethylated in cancer 2 +1.4 
A_51_P172241 TC1312974   +1.4 
A_52_P90101 AK036209; Sca2 spinocerebellar ataxia 2 homolog (human) +1.4 
A_52_P360453 AK084271; 3110052M02Rik RIKEN cDNA 3110052M02 gene +1.4 
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Table 1.7 (continued) 
 
A_52_P102022 AK017641; 5730446C15Rik RIKEN cDNA 5730446C15 gene +1.4 
A_52_P369946 CB850089   +1.4 
A_51_P461947 NM_177298 9030221M09Rik RIKEN cDNA 9030221M09 gene +1.4 
A_52_P407755 AK009137; 2310032D16Rik RIKEN cDNA 2310032D16 gene +1.4 
A_52_P499917 AK051838; D930046L20Rik RIKEN cDNA D930046L20 gene +1.4 
A_52_P386468 NM_007700 Chuk conserved helix-loop-helix ubiquitous kinase +1.4 
A_52_P481097 AK086528; Lztfl1  +1.4 
A_51_P458230 AK054427;   +1.4 
A_52_P676492 AK032320 Brd8  +1.4 
A_52_P432464 AK053863; Luc7l2 LUC7-like 2 (S. cerevisiae) +1.4 
A_52_P1100217 AK051484;   +1.4 
A_52_P337948 AK088459 Tnik  +1.3 
A_52_P323215 NM_019570 Rev1l REV1-like (S. cerevisiae) +1.3 
A_52_P6451 AK090341   +1.3 
A_52_P374669 XM_359326 Jarid1a  +1.3 
A_52_P190807 AK032690   +1.3 
A_52_P276412 AK011886; Atipif11  +1.3 
A_52_P456702 AK045162; B930046C15Rik RIKEN cDNA B930046C15 gene +1.3 
A_52_P376103 AK042630;   +1.3 
A_52_P273674 BC019581;XM_619603 
4930413O22
Rik RIKEN cDNA 4930413O22 gene +1.3 
A_52_P5549 NM_026583 5830415L20Rik RIKEN cDNA 5830415L20 gene +1.3 
A_52_P61273 BC066768 Leng8  +1.3 
A_52_P527329 AK089867; 9030025P20RIK  +1.3 
A_52_P577116 AK029399; Pik3ca phosphatidylinositol 3-kinase, catalytic, alpha polypeptide +1.3 
A_51_P476660 XM_139743 Mllt4 
myeloid/lymphoid or mixed lineage-
leukemia translocation to 4 homolog 
(Drosophila) 
+1.3 
A_52_P268720 AK122645 Helz  +1.3 
A_52_P107681 AK028731; Ylpm1 YLP motif containing 1 +1.3 
A_51_P221008 AK028276; 3222401L13Rik RIKEN cDNA 3222401L13 gene +1.3 
A_51_P133037 NM_008889 Ppp1r14b protein phosphatase 1, regulatory (inhibitor) subunit 14B +1.3 
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Table 1.7 (continued) 
 
A_52_P668157 AK011905; NCAM1 Neural cell adhesion molecule1 +1.3 
A_52_P342202 NM_027696 4933425I22Rik RIKEN cDNA 4933425I22 gene +1.3 
A_52_P283055 TC1248463   +1.3 
A_51_P261107 NM_139144 Ogt 
O-linked N-acetylglucosamine 
(GlcNAc) transferase (UDP-N-
acetylglucosamine:polypeptide-N-
acetylglucosaminyl transferase) 
+1.3 
A_52_P620432 AK019968; 2410005O16Rik RIKEN cDNA 2410005O16 gene +1.3 
A_51_P192089 NM_028228 Pinx1 PIN2/TRF1-interacting protein +1.3 
A_52_P507277 NM_025789 Rshl2 radial spokehead-like 2 -1.3 
A_51_P486479 NM_024456 Rab5c RAB5C, member RAS oncogene family -1.3 
A_51_P267544 NM_013522 Frg1 FSHD region gene 1 -1.3 
A_51_P110576 NM_011175 Lgmn legumain -1.3 
A_51_P261689 AK003078; UBE2S  -1.3 
A_52_P476357 NM_016878 Dnpep aspartyl aminopeptidase -1.3 
A_51_P439824 NM_018771 Rgs19ip1 regulator of G-protein signaling 19 interacting protein 1 -1.3 
A_52_P461292 NM_008753 Oaz1 ornithine decarboxylase antizyme -1.3 
A_51_P261351 NM_026246 Mrpl49 mitochondrial ribosomal protein L49 -1.3 
A_52_P614336 NM_011116 Pld3 phospholipase D3 -1.3 
A_51_P140141 AK013263; 1500019G21Rik RIKEN cDNA 1500019G21 gene -1.3 
A_51_P375227 NM_009954 Bcar1 breast cancer anti-estrogen resistance 1 -1.3 
A_52_P362128 BC025640;XM_130932 Pygo2 pygopus 2 -1.3 
A_52_P187787 NM_023231 Stoml2 stomatin (Epb7.2)-like 2 -1.3 
A_51_P435333 NM_027151 Dctn2 dynactin 2 -1.4 
A_52_P585104 NM_010219 Fkbp4 FK506 binding protein 4 -1.4 
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Table 1.8 
Significantly differentially expressed genes by developmental stage ANOVA FDR .05 
 
Probe Set 
P 
Value 
Gene Name Gene Symbol Genebank 
Expression 
with age 
A_51_P431397 0.0199 Nucleoporin 214 Nup214 AK040284 Down 
A_52_P98630 0.0195 interleukin 3 Il3 NM_010556 Up 
A_51_P314161 0.0195 queuine tRNA-ribosyltransferase 1 Qtrt1 NM_021888 Up 
 
Discussion 
Angiotensin II  binds to two receptors, AGTR1 and AGTR2.  In the absence 
of AGRT2, it would be expected that all angiotensin II would be bound to AGTR1.  
Without the regulating effect of AGTR2, the AGTR1 signaling cascades should be 
unchecked. The absence of AGTR2 did not cause a detectable increased expression 
of AGTR1 in the brains of E15 or P1 Agtr2-/y mice.  There was also no difference in 
expression of genes in the RAS between knockouts and controls.  Our results show 
that genes downstream of AGTR1 are up-regulated in the absence of AGTR2. 
 Our results also suggest that AGTR2 may have different effects on the 
developing brain at different developmental stages as only two genes, Pisd and Rab 
30 were found to be in common between the two developmental stages in the final 
lists of significantly differentially expressed genes. 
 The largest gene categories represented as over-expressed in E15 Agtr2-/y  
brains are transcription factors and genes in the AGTR1 pathway (Table 1.9).  Other 
categories of genes are transferases, kinases, genes involved in microtubule and actin 
processing, cell adhesion, protein transport and/or binding, nucleic acid binding, 
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immunity, cell cycle arrest, ubiquitin/proteasome function and a protein 
phosphatase.  Two genes, Akap9 and Mtap2 are involved in the up-regulation of 
NMDA receptors (Lin et al. 1998).  
In the E15 Agtr2-/y brains, genes predominantly involved in apoptosis were 
found to be down-regulated.   This is consistent with previous findings that AGTR2 
is a mediator of apoptosis (Yamada et al. 1996).  A summary of functions for 
dysregulated genes in the E15 knockouts is presented in Table 1.9 and Table 1.10. 
 
Table 1.9 
Up-regulated Gene Categories of E15 Agtr2-/y Brains 
 
Agtr1-related Functions  
Pisd 
Pde4B 
Plcxd3 
Prei4 
Dgkh 
Sla2 
Ca2+  binding Riken 
 
Transferases  
Ncoa6Ip 
Dgkh 
Nat5 
Trio 
 
Transcription Factors  
Prdm16         L3mbtl3 
Zfp291          Zfp46 
C77370 
Aff3 
Taf1 
Klf7 
Arid4a 
Kinases  
Bmp2k 
Akap9 
 
Microtubules/Actin  
Mtap2             Fnbpi1 
Mtap1B 
Akap9 
Protein 
Transport/Binding  
Pam              Nbeal1 
Rab30           Ncoa6Ip 
Atxn2            Shprh 
Cell Adhesion  
Btbd9 
Pcdh9 
Sla2 
Nucleic Acid Binding  
Nol8 
Helz 
Trio 
Immunity  
H2-Bl 
Sla2 
 
Cell Cycle Arrest  
Sesn3 
Ubiquitin/Proteasome 
Ube1l2 
Protein Phosphatase 
Ppm1l 
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Table 1.10 
Down-regulated Gene Categories of E15 Agtr2-/y Brains 
 
Agtr2-related Functions 
Ptges2 
Pla2g4b 
Ube2m 
Cell Cycle Arrest 
Plk1 
Transferase 
Plk1 
Chrac1 
Cell Proliferation 
Gfer 
Translation 
Mrps12 
Immunity 
H2-t10 
 
Up-regulated genes in the P1 Agtr2-/y brains were over-represented by genes 
involved in protein binding and transport (Ercc8, Notch2, Hdh, Timm9, Rev1l, 
Rab14, Rab30, Sept11 and Hook1).  Also up- regulated were genes involved in RNA 
processing, (Rbm26, Rbm18, Sfrs10, Rian, Sf3b3, Hnrpd1), DNA binding, (Ankrd 
11, Rab14, Ccar1), transcription (Prr8, Ercc8, Nr1i3) and glutamate metabolism (Gls 
and Gria4).  Several genes involved in cell adhesion (Ptprs, Pvr14, Ncam1 and Nrli3) 
as well as cytoskeleton and microtubule expression (Add1, Hook1 and Eml5) were 
also represented.  A complete summary of the categories is found in Table 1.11. 
Examination of the P1 results show that some of the genes involved histone 
modification (Nasp and Ppp2cb), nucleotide metabolism (Itpa), NADP+ activity 
(Idh1), protein ubiquination (Fbox11 and Ndfip2) rRNA processing (Frg1), 
chromatin remodeling (CHMP5) and calcium ion binding (Creld1).  The list is 
summarized in Table 1.12. 
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Table 1.11 
Functions of Up-regulated Genes of P1 Agtr2-/y  Brains 
 
Agtr1 Pathway 
Mapk8 
Pisd 
Chka 
Protein Binding/Transport 
Ercc8            Rab30 
Notch2          Rab14 
Hdh               Sept11 
Timm9           Hook1 
Rev1L 
RNA Processing 
Rbm26 
Rbm18 
Sfrs10 
Rian 
Sf3b3 
Hnrpdl 
Cell Adhesion 
Ptprs 
Pvr14 
Ncam1 
Nrli3 
Cytoskeleton/Microtubules
Add1 
Hook1 
Eml5 
DNA Binding 
Ankrd 11 
Rab14 
Ccar1 
Transcription 
Prr8 
Ercc8 
Nr1i3 
Cell Cycle Control 
Nudcd3             Atpif1 
Gpiap1 
Ccar1 
Kinases 
Mapk8 
Chuk 
Anti-apoptosis 
Hdh 
Notch2 
Perception of Sound 
Timm9 
Ercc8 
Ubiquitin/Proteasome 
Usp15 
Psmd7 
Glutamate 
Metabolism 
Gls 
Gria4 
Protein Phosphatase 
Ptprs 
 
 
Table 1.12 
Functions of Down-regulated Genes of Agtr2-/y P1 Brains  
 
Chromatin Remodeling 
Chmp5 
Histone Binding 
Nasp 
Ppp2cb 
Nucleotide Metabolism 
Itpa 
Lysosome Organization 
Chmp5 
Proteolysis 
Dnpep 
Protein Ubiquination 
Fbxo11 
Ndfip2 
Protein Modification 
Zdhhc2 
rRNA Processing 
Fbl 
Ca2+  Binding 
Creld2 
NADP+ Activity 
Idh1 
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 Pathway Studio (Ariadne, Rockville, MD USA) was used to visualize 
common functions for the genes down-regulated in the E15 Agtr2-/y brains.   Three 
genes down-regulated in E15 Agtr2-/y  brains Ptges2,  H2-T10 (HLA-F) and Ube2m, 
are all involved in inducing apoptosis (Figure 1.11), consistent with previous findings 
that AGTR2 induces apoptosis.  Plk1 has been shown to cause cell proliferation and 
inhibit apoptosis (Reagan-Shaw and Ahmad 2005; Jang et al. 2006).  Pla2g4b is a 
phospholipase and phospholipases are in the AGTR2 signaling pathway.   
 
 
 
Figure 1.11  E15 down-regulated genes involved in apoptosis.  Yellow squares = cell 
functions, pink shapes = proteins, purple gradient = E15 list. 
 
Examining the genes up-regulated in the Agtr2-/y  E15 brains with 1.5 fold or 
greater expression reveals a complex picture. AGTR2 has previously been shown to 
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down-regulate MAP1B but up-regulate MAP2 in PC12W cells (Stroth et al. 1998). In 
this study Mtap2 and Mtap1b are both up-regulated in the E15 Agtr2-/y brains.  
MAP2 (Mtap2) has previously been shown to be phosphorylated by JNK and 
subsequently defines dendritic shape in the brain (Bjorkblom et al. 2005) Map2  is 
found in the dendrites and is crucial for microtubule stability (Stroth et al. 1998).  
Map1b is found in growth cones and is needed for neurite outgrowth (Stroth et al. 
1998).   It remains to be seen if these two genes (Mtap2 and Map1b) play a role in 
the defective dendritic spine morphology noted in Agtr2-/y mice (Maul, unpublished 
data).    These genes also regulate actin along with two genes C1orf39 (also known as 
Fnbp1l) (Ho et al. 2004) and Sla2  (Sun et al. 2005) which are also up-regulated in 
E15 Agtr2-/y brain.  Several other up-regulated genes, Akap9, Fnbp1l, as well as 
Mtap2 and Map 1B are associated with microtubule function (Figure 1.12). 
  46                         
 
 
Figure 1.12  Genes up-regulated in Agtr2-/y  brains affecting microtubule expression 
as well as other cell functions vital to brain development and function.  Genes 
highlighted in purple are from the E15 list.  (FLJ20274 = Fbl)   Yellow squares = cell 
function, orange hexagons = functional class,  pink ovals = proteins, gray ovals = 
cell part 
 
 Peptidylglycine alpha-amidating monooxygenase (Pam),  was found to be 
more than two-fold up-regulated in the E15 knockouts (Table 1.2).  This gene 
contains two catalytic domains that work sequentially to catalyze neuroendocrine 
peptides and is needed for signal transduction and receptor recognition (Driscoll et 
al. 2006).    
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 Prdm16, PR domain containing 16, (also known as Mel 1) shared the highest 
level of expression in the E15 knockouts.  This gene codes for  a transcription factor 
containing several zinc finger domains and is associated with myelodysplastic 
syndrome and acute myloid leukemia(Nishikata et al. 2003; Xinh et al. 2003).  Several 
zinc fingers and helicases are up-regulated in the E15 knockouts: Zfp291, Zfp46, 
Helz and Shprh. 
 Genes involved in regulation of microtubules are also well represented in the 
over-expressed genes of the P1 knockouts.  Add1, Eml5, Hdh, Hook1, Nudcd3 and 
Sept11 all affect microtubules. 
Notch2 and Hdh are up-regulated in P1 knockouts and both have anti-
apoptotic effects (Rigamonti et al. 2000; Duechler et al. 2005; Leavitt et al. 2006).  
Hdh up-regulates  brain derived neurotrophic factor (BDNF) (Zuccato et al. 2003) 
and associates with the EGF pathway potentially causing overgrowth of neuronal 
cells.  Notch2 is also negatively associated with glial differentiation (Tanaka et al. 
1999). 
In the P1 knockouts several overexpressed genes, Hdh, Gria4, and Gls, were 
found to be involved in glutamate metabolism.  Glutamate metabolism is integral to 
NMDA receptors which are essential in neuronal development and synaptic 
plasticity.   
Down-regulated in the P1 brains are Fbox11 and Ndfip2, which are involved 
in the ubiquitin-proteasome system which contributes to cellular differentiation (Li et 
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al. 2007).  Also down-regulated in the P1s are Nasp and Snf7 which are involved in 
histone modification.   Cells preparing to undergo apoptosis often have histone 
modification (Janigro 2006).   Several other genes involved in Agtr2 functions, such 
as two phosphataseses, Itpa and Pp2cb are also down-regulated in the P1 brains.  
Idh1 and Ndfip2 are genes involved in the NF-Kappa pathway in apoptosis. Fbl and 
Frg1 are involved in RNA processing, and are also nucleolar proteins. 
 Mapk8, map kinase 8, (also known as JNK1) is part of the AGTR1 
signaling cascade and is one of the most significantly up-regulated genes in the P1 
knockout brains. It has been shown to be a regulator of morphogenesis in early 
nervous system development (Tararuk et al. 2006).  JNK1 (Mapk8) phosphorylates 
the microtubule depolymerizing factor SCG10 which determines microtubule 
stability and axodendritic length (Tararuk et al. 2006). 
The up-regulation of Chuk (also known as IKK1) is significant in that it is 
also influenced by angiotensin II (Wu et al. 2006), and activates the NF-kappa-B 
complex, which in turn causes cell proliferation and anti-apoptotic effects (Luo et al. 
2005).   (Figure 1.13). 
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Figure 1.13   Interaction and common targets of Chuk, Agtr1 and Agtr2.    Note that 
Chuk, Agtr2 and Agtr1 up-regulate cell proliferation, but also are involved in 
apoptosis.  Purple shapes = genes from P1 list, pink shapes = proteins, orange 
hexagons = functional classes, yellow squares = cellular functions.   
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Other important up-regulated genes in the P1 list are cell adhesion genes.   
Ncam1, neural cell adhesion molecule 1,  has been associated with NMDA receptors 
(Sytnyk et al. 2006) and the inhibition of cell death (Bussolati et al. 2006).   Pvrl4 is 
also a cell to cell adhesion gene (Reymond et al. 2001).  Ncam1, Gria4, Nr1i3 and 
Mapk8 all share several important neurological functions (Figure 1.14). 
 
Figure 1.14  Genes with common neurological functions that are up-regulated in P1 
knockouts.  Purple shapes = genes from P1 list,  pink shapes = proteins, orange 
hexagons = functional classes, yellow squares = cellular functions 
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It is important to note that this study used total RNA isolated from whole 
brain for gene expression profiling.  Previous in-situ hybridization work (Nuyt et al. 
1999) has shown that Agtr2 gene expression is varied in both expression level and 
location dependent upon developmental stage.    In-situ hybridization of the 
dysregulated genes may further elucidate potential roles of these genes in the 
developing brain. 
Our study shows that the absence of Agtr2 gene expression in the developing 
brain causes an up-regulation in AGTR1 activities such as cell proliferation.   A more 
novel finding for both developmental stages E15 and P1 is genes connecting with 
NMDA receptor function are increased in the Agtr2-/y brain, and may possibly 
contribute to abnormal brain development.  The up-regulation of genes involved in 
cell adhesion point to a contribution to abnormal synaptic connectivity.   Our results 
support other studies that have shown abnormal dendritic spines in Agtr2-/y mice 
might be caused by abnormal microtubule activity.  We found genes that affect 
micro-tubules are up-regulated at both developmental stages in the Agtr2-/y mouse 
brains.  This study further adds to the hypothesis that AGTR2 contributes to the 
developing brain by influencing cell morphology and synaptic connectivity.  Further 
analysis might reveal if some of the genes influenced by AGTR2 may also contribute 
to the pathophysiology of mental retardation. 
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IDENTIFICATION OF AGTR2 INTERACTING PROTEINS 
 IN FETAL BRAIN 
 
 
  Many genes can have different expression patterns and functions depending 
on the developmental state of the organism.  Genes expressed in the brain during 
embryonic and fetal development can be different than those expressed in the adult 
brain.  Understanding the interactions of different proteins in the developing brain is 
important to understanding the etiology of mental retardation (MR), which affects 
approximately 1-3% of the population (Chelly and Mandel 2001) and brain 
development. 
 The angiotensin II type receptor (AGTR2) is a seven transmembrane 
receptor consisting of 363 amino acids (Mukoyama et al. 1993).  The AGTR2 gene is 
located on human chromosome Xq23 and consists of 3 exons (Gard 2002).  It is 
expressed at high levels in fetal brain (Nuyt et al. 1999), but is predominately  
expressed in the cerebellum of the adult brain, though it is up-regulated in some 
cases of neurological disease (von Bohlen und Halbach and Albrecht 2006).  
Angiotensin II has been shown to affect not only physiological behaviors related to 
water intake, but also affecting cognition and emotional centers (Gard 2002).   
Several mutations in AGTR2 have been characterized in humans.  Specifically, a 
G21V mutation in the N-terminal, an A324G and I337V mutations in the C-terminal 
and a FSPhe133 deletion and I53F mutation in the transmembrane domain have been 
described in individuals with MR(Vervoort et al. 2002; Ylisaukko-ojo T 2004).  Also, 
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several proteins (Erb3, PLZF, ATIP, NHE6) have been found to interact with 
AGTR2 through in-vivo and in-vitro studies (Knowle et al. 2000; Senbonmatsu et al. 
2003; Nouet et al. 2004; Pulakat et al. 2005). 
The amino terminal of AGTR2 has been shown to be necessary for the binding 
of angiotensin II (Yee et al. 1998).  The second intracellular loop of AGTR2 is 
necessary for  G-protein signaling (Moore et al. 2002).  Studies using Xenopus oocytes 
showed that the C-terminus of the 3rd intracellular loop of AGTR2 is necessary to 
lower cGMP levels mediated by AGTR2 and that the C-terminal tail is necessary for 
negative regulation of cGMP  (Pulakat et al. 2005).  Previous yeast two-hybrid 
studies have found that the 3rd intracellular loop of AGTR2 interacts with v-erb-b2 
erythroblastic leukemia viral oncogene homologue, (ERBB3) (Knowle et al. 2000), 
and solute carrier family 9 Na/H exchanger isoform 6, (NHE6) (Pulakat et al. 2005).   
The C-terminal domain has been found to interact with promyelocytic leukemia zinc 
finger protein (PLZF) (Senbonmatsu et al. 2003) and AGTR2 interacting protein, 
(ATIP) (Nouet et al. 2004).   
In light of these findings, our goal is to identify proteins that interact with 
AGTR2 in the developing brain and to further understand AGTR2 mediated 
signaling in developing brain. Using a yeast two hybrid system, individual constructs 
of either the amino or carboxy terminal of AGTR2 were made and screened against 
a human fetal brain cDNA library.  Here we describe the interaction between the 
amino terminal of AGTR2 and three proteins:   ASMTL, GNB2L1 and NGLY1. 
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Materials and Methods 
Cloning vector  and Yeast Strains:  The Saccharomyces cerevisiae strain AH109 (Ade-, 
Met+, Trp-, Leu-, His-) was used from the MATCHMAKER Gal4 2-Hybrid System 
Three (Clontech).  The plasmid pGBKT7 (Clontech) two-hybrid bait vector was 
used to express a protein of interest in fusion with the GAL4 binding domain (BD) 
and the interacting protein.  It contains a kanamycin resistance gene for selection in 
E. coli, and when transformed into yeast it is prototrophic for tryptophan.  The 
plasmid pACT2, a yeast two-hybrid prey vector (CLONTECH) was used to 
construct translational fusions of the GAL4 activation domain (AD) and the protein 
of interest.  It contains an ampicillin resistance gene for selection in E. coli, and is 
prototrophic for leucine when transformed into the AH109 strain. 
  Construction of bait vectors:  Primers were designed with an EcoRI adapter 
sequence to make a PCR product of the first 45 amino acids of AGTR2 and a 
separate primer set for the last 52 amino acids of AGTR2.  The amplicon was ligated 
into the PCR2.1 vector (Invitrogen).  Positive clones were selected and cultured in 
LB with 20ng/ml of ampicillin.  Plasmid DNA from selected clones was isolated 
with Qiagen Mini-prep kits according to manufacturer instructions (Qiagen).  
Plasmids were sequenced using M13 primers, F- 5’ CTGGCCGTCGTTTTAC 3’  
and R- 5’ GTCATAGCTGTTTCCTG 3’ and DYEnamic Dye Terminator Cycle 
sequencing Kit (GE Healthcare) using the automated MegaBACE 1000 DNA 
Analysis system (GE Healthcare).  Sequences were analyzed using the DNASTAR 
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program (Madison, WI).  Plasmid DNA was digested with EcoRI (New England 
Biolabs), electrophoresed and the desired insert was gel isolated and ligated into an 
EcoRI digested pGBKT7  plasmid.  Ligation was achieved using the Ligate-IT Rapid 
Ligation Kit (USB) according to manufacturer instructions. Plasmid DNA was 
isolated from positive clones.  The DNA was sequenced to verify that they were in-
frame with the Gal4 binding domain of pGBKT7.   The bait constructs containing 
AGTR2 gene inserts were transformed using the LiCl method into yeast strain 
AH109 (Clontech) according to manufacturer’s instructions.  After transformation, 
yeast was plated on SD media without tryptophan which selects for the pGBKT7 
plasmid.    To verify that the desired proteins were being produced, proteins from 
the transformed yeast of each construct were harvested and purified according to 
manufacturer instructions (Clontech 1999).   Proteins were electrophoresed on a 
12% SDS-Page acrylamide gel, transferred to supported nitrocellulose and then 
hybridized with the Gal4 binding domain antibody (Santa Cruz Biotechnology).  
Each construct was also tested for auto-activation by transforming the plasmid DNA 
into AH109 yeast with an empty activation domain vector, plating on SD media 
lacking leucine, tryptophan, adenine and histidine and containing α-galactosidase (-
AHLT αgal) and verifying there was no positive interaction.  A positive interaction is 
defined as colonies that can grow on –AHLT αgal media and turn blue.  Neither 
construct grew on selective media when transformed with an empty activation 
domain vector. 
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Amplification of fetal brain library:    A human fetal brain library consisting of 
cDNA from 4-5 fetuses of 20-25 weeks gestational age, was purchased from 
CLONTECH.  This library contains cDNA fragments of 400 to 4500 bp inserted 
into the pACT2 plasmid with EcoRI and XhoI restriction sites in frame with the 
GAL4 activation domain (AD).  pACT2 has the selection marker –leu for selection in 
yeast and is ampicillin resistant for selection in E. coli.  The library was amplified to 3 
x 106coverage according to manufacturer instructions (Clontech 1999).  The 
collected amplified library plasmid DNA was purified using the Qiagen Mega-Prep 
kit according to manufacturer specifications (Qiagen). 
Yeast transformation and screening:  Saccharomyces cerevisiae strain AH109 was cultured 
in Yeast extract Peptone Dextrose with 0.03% adenine hemisulfate media (YPDA) 
until reaching log phase.  One microgram of each the bait plasmid and the library 
plasmid were co-transformed into the yeast using the LiCL method with the 
Yeastmaker™ Yeast Transformation Kit (CLONTECH).    Transformed yeast was 
collected and then cultured  in YPDA for 1-3 hours prior to plating on –LT and –
AHLTα-gal media plates.  Plates were then incubated at 30º C for 5 days, and then –
LT plates were counted and  co-transformation efficiency was calculated using the 
following formula (Clontech 1999): 
Count the colonies (cfu) formed on a diluted –LT SD plate 
              ________CFU x total suspension volume (µl)_______     =  cfu/µg DNA 
              Volume plated (µl) x dilution factor x µg library plasmid 
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  Transformation efficiency is then used to calculate the number of clones screened 
using the following formula:  cfu/µg x µg of library plasmid used = # of library 
clones screened (Clontech 1999).  Colonies growing on –AHLTα-gal and turning 
blue were selected and re-plated in a grid pattern on –AHLTα-gal plates and 
incubated at 30ºC for 5 days with a positive control reference on each plate.  
Colonies that grew and were blue on the second plating were considered positive and 
were selected for follow-up studies.   The selected library plasmids were isolated 
using the Zymoprep II yeast plasmid isolation kit (ZymoResearch).  Isolated 
plasmids were amplified with pACT2 specific primers:  F- CTATTCGATGATG-
AAGATACCCCACCAAACCC and R- GTGAACTTGCGGGGTTTTTCAG-
TATC with the following PCR conditions: 95ºC for 5 min., 95ºC for 30 sec.,  64ºC 
for 30 sec., 72ºC for 45 sec. for 30 cycles followed by a 7 min. extension at 72ºC.  
Amplicons were purified and then sequenced as previously described.  Sequences 
were analyzed using BLASTN and BLASTX algorithms from the NCBI website 
(http://www.ncbi.nlm.nih.gov/BLAST).  Clones containing sequence of only a 3’ 
UTR were discarded.  Isolated clones with sequence matching a coding region of a 
gene were selected for further analysis.    Yeast plasmid DNA from clones selected 
for further analysis was amplified by transforming into competent E. coli and 
selecting for ampicillin resistance.  Plasmid DNA was purified from bacterial 
colonies as previously described.  The plasmid DNA was then co-transformed with 
the bait vector plasmid DNA into AH109 yeast and plated on –LT and –AHLTα-gal 
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media.  Clones that were positive for this test were co-transformed into AH109 yeast 
with the empty bait vector pGBKT7 and plated on –LT and –AHLT α-gal media. 
Clones that grew with the empty vector on –AHLT α-gal were considered false 
positives and discarded.    
 Co-immunoprecipitation   Co-immunoprecipitation was performed using the 
Matchmaker™ CO-IP kit (CLONTECH). The pACT2 vector does not contain a T7 
promoter sequence and this was added to the selected prey plasmids via PCR  with 
the following primers: F- 5’AAAATTGTAATACGACTCACTATAGGGCGACC-
CGCCACCATG 3’ and R- 5’ – ACTTGCGGGGTTTTTCAGTATCTACGAT 3’  
with PCR conditions as recommended by the manufacturer (Clontech 2006) as 
follows:  94ºC for 1 min., followed by 2 cycles of 94ºC for 15sec., 72ºC for 5 min., 
followed by 2 cycles of 94ºC for 15 sec. 70ºC for 5 min., followed by 94ºC for 15 
sec., 68ºC for 5 min. for 21 cycles, followed by a 7 min. extension at 68ºC.   The bait 
plasmid and positive clone prey plasmids were translated using the Promega TnT 
Coupled Reticulocyte System (Promega) and 35S-methionine according to 
manufacturer instructions.  In brief, after the initial T7 translation proteins from the 
candidate clones were combined with protein of bait plasmid and incubated with 
either the c-Myc or HA antibody and then co-immunoprecipitated with Protein A 
beads according to manufacturer instructions (Clontech 2006).  This consisted of 
adding 10 µl of combined lysate to 3µl of prepared Protein A beads and rotating at 
low speed for at least 1 hour at room temperature.  After rotating, beads were 
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washed six times with manufacturer provided wash solution and then resuspended in 
20µl of 0.1% SDS-BPB loading dye.   Protein beads were denatured at 95ºC for 5 
minutes, electrophoresed on a 15% SDS polyacrylamide gel and then electroblotted 
on supported nitrocellulose.   Dried nitrocellulose membranes were imaged 
radiographically. 
Quantitative RT-PCR  RNA from transformed human lymphocyte cell lines was 
extracted with the RNeasy RNA extraction kit (Qiagen).  Samples were further 
treated with Turbo DNase-free (Ambion).  Primers were designed using Primer Bank  
(http://pga.mgh.harvard.edu/primerbank/index.html).  The list of primers is 
detailed in Table 2.1. 
Table 2.1 
Primers for Quantitative RT-PCR of AGTR2 Interactors 
 
Primer 
Name 
Primer Sequence – 5’ to 3’ Annealing Temp. 
ºC 
ASMTL F- CAACCGGCTGTACCAGAAAGAC 
R- GATCGTGTCCGCTCCAATG 
61 
ASMTL2 F- CAACCGGCTATACCAGAAAGAC 
R- GATCGTGTCCGCTCCAATG 
60 
GNB2L1 F- GACCATCATCATGTGGAAACTGA 
R- CCGTTGTGAGATCCCAGAGG 
60 
GAPDH F- GAAGGTGAAGGTCGGAGTC 
R- GAAGATGGTGATGGGATTTC 
61 
NGLY1 F- GACTGGCACATGGTATATTTGGC 
R- TGCTGTATCAGATCGCAATTTCC 
55 
WDR1 F- GGAGCACCTGTTGAAGTATGAG 
R- GAAGAGCCACTATCCCAGAGG 
55 
 
Quantitative RT-PCR was carried out using I-Script One-Step RT-PCR kit with Sybr 
Green (Biorad) in a total volume of 25 µl on the Biorad I-cycler (Biorad).  All 
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samples were analyzed in triplicate using 5 ng total RNA and analyzed using the 
standard curve method (Larionov et al. 2005). 
Genomic PCR  Human DNA isolated from lymphocytes was amplified as previously 
described in Chapter One. The following primers were used:  ASMTLex13F- 5’ 
TCTCCCATCCCTATCCCTAGA 3’ and ASMTLex13R- 5’ TGACGGAGT-
GTTCAATGGAG 3’.  The following PCR conditions were used: 95ºC for 5 min., 
followed by 95ºC for 30 sec., 60ºC for 30 sec., 72ºC for 30 sec. for 30 cycles 
followed by a 7 min. 72ºC extension.  This produces a 400 bp amplicon.  For 
densitometry analysis 100ng of each patient sample was used in the PCR.  After gel 
electrophoresis on a 1.8% agarose gel, samples were analyzed using the densitometry 
program of the Alpha-Imager (AlphaInnotech).    Rf values of each sample were 
then compared to quantitate gene dosage. 
Results 
Identification of candidate interacting proteins 
 Proteins from the C-terminal and N-terminal constructs, the empty bait 
vector pGBKT7 and AH109 yeast were isolated and analyzed by Western blot.  An 
antibody to the Gal4 BD domain was hybridized to the blot  and confirmed that 
both constructs were producing the expected protein.  Western blot analysis showing 
the appropriate sizes for each construct is shown in Figure 2.1. 
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Figure 2.1– Western blot using Gal4BD antibody of yeast transformed with no 
construct (AH109), pGBKT7 with the AGTR2 C-terminal, pGBKT7 with the 
AGTR2 N-terminal,  and pGBKT7 alone (pGBKT7).   AGTR2 constructs are 
expected to be ~5kD larger than the empty vector. 
 
The C-terminal intracellular domain of AGTR2 construct was screened 
against the human fetal brain library.  A total of 2.11 x 106 clones were screened.  No 
positively interacting clones were identified. 
Screenings of the N-terminal extra-cellular domain totaling 944,700 clones 
resulted in 376 positive clones.  Positive clones were then restreaked on –AHLT α-
gal plates.  Of these, 108 clones were selected for sequencing.  Sequences were 
analyzed using BLASTN and BLASTX (http://www.ncbi.nlm.nih.gov/BLAST/) to 
identify clones with inserts in frame and coded for a protein.  Of the 108 clones 
sequenced, 39 were selected for further testing as they fit this criteria.   Further 
~23 kDa 
17.5 kDa 
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testing included re-interacting the selected prey plasmid with the N-terminal 
construct via yeast transformation and also interacting it with the empty pGBKT7 
plasmids.  Library plasmids that failed to re-interact with N-terminal construct or 
interacted with the empty pGBKT7 plasmid were considered false positives.  After 
this screening, 19 clones remained, representing 7 genes, which are detailed in table 
2.2. 
Table 2.2 
Candidate Gene Results from Screening of AGTR2 N-term 
 
Gene 
symbol 
Gene ID Number of 
clones 
HA Co-IP C-myc Co-
IP 
Protein size
Asmtl NM_004192 1 yes yes 15 kd 
Aplp1 NM_005166 12 yes yes 8 kd 
Chrom 12p  1 No translation N/A N/A 
Chrom 1  1 No translation N/A N/A 
Gnb2L1 NM_006098 2 yes yes 20 kd 
Ngly-1 NM_006098 1 yes yes 10 kd 
Wdr1 NM_017491 1 yes yes 20 kd 
 
Confirmation of AGTR2 interacting proteins 
Clones listed in Table 2.2 were further analyzed by co-immunoprecipitation 
after T7 translation.  Clones Chrom12p and Chrom1 were eliminated as they failed 
to translate.  The other five interaction candidates (ASMTL, APLP1, GNB2L1, 
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NGLY-1 and WDR1) were found to make a specific protein in a T7 translation 
assay.   These clones are shown on selective yeast media with positive and negative 
controls in Figure 2.2   
            
 
          
 
Figure 2.2  Positive clones on non selective (-LT) and selective (-AHLT) media.  
Positive clones turn blue in the presence of alpha-galactosidase.  All clones 
containing both AD and BD plasmids grow on –LT media.  Only clones with 
interacting proteins grow on –AHLTαgal media and turn blue. 
-LT plate 
-AHLT α-gal plate
ASMTL/N-term
ASMTL/Nterm
WDR1/Nter
WDR1/Nter
NGLY1/Nterm
NGLY1/Nter
GNB2L1/Nter
GNB2L1/Nter
GNB2L1/C-term 
GNB2L1/C-term 
Negative ctrl 
Negative ctrl 
Positive ctrl 
Positive ctrl 
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The positive control consisted of the pVA3-1 (containing the Gal4BD and p53T 
antigen) and pTD1-1 (containing the Gal4AD and SV40 large T antigen).  This 
control grows on –AHLTαgal media and demonstrates strong β-Galactosidase 
activity.   The negative control consisted of pLAM5’ (containing the Gal4BD and 
human β-lamin) and pTD1-1.  This control grows on –LT media, but will not grow 
on –AHLTαgal media.  
Of these clones, three were verified by co-immunoprecipitation (Figures 2.3 and 
2.5).    APLP1 and WDR1 were also found to co-immunoprecipitate with the 
pGBKT7 murine p53 control construct (figure 2.4) and thus were considered false 
positives.  Co-immunoprecipitation was confirmed using both the c-Myc antibody, 
which is specific for the bait plasmid, and the HA antibody, which is specific for the 
library prey plasmid.  Three proteins, ASTML, GNB2L1 and NGLY1, were 
identified as positive interactors.   
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Figure 2.3:  CO-IP with c-Myc ab. 1= pGADT7 SV40 and pGBKT7 Murine p53 
controls, 2 = APLP1 and ECD, 3 = ECD alone, 4 = NGLY1 and ECD  5 = Asmtl 
with ECD, 6 = GNB2L1 and ECD  
 
 
Figure 2.4  CO-IP of candidate proteins and control with HA antibody.  1 = 
pGADT7 SV40 and pGBKT7 Murine p53 controls,  2 = APLP1 and pGBKT7 
control, 3 = ASTML and pGBKT7 control 4 = GNB2L1 and pGBKT7 control 5 = 
NGLY1 and pGBKT7 control 6 = WDR1 and pGBKT7 control.  In lane 2 a band 
corresponding to  the pGBKT7 control is seen, indicating that APLP1 is a 
false=positive.   
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Figure 2.5:  CO-IP of candidate proteins and AGTR2 N-terminal with HA antibody.  
1 = ASMTL and ECD, 2 = GNB2L1 and ECD, 3 = NGLY1 and ECD.  The HA 
antibody did not give as clean a result as the c-Myc antibody, causing extra bands on 
the image. 
 
Evaluation of G21V mutation with candidate AGTR2 interactors  
An N-terminal extracellular domain construct containing the G21Vmutation in 
the pGBKT7 vector  was interacted individually with APLP1, ASMTL, GNB2L1, 
NGLY1 and WDR1.  This construct interacted with all five of these clones. 
Analysis of Candidate Protein Specificity 
 GNB2L1 has previously been shown to interact with the angiotensin II 
receptor-associated protein (Agtrap) which in turn interacts specifically  with the 
carboxy terminal of AGTR1  (Wang et al. 2002).    To test the specificity of 
GNB2L1 binding to AGTR2, the positive clone containing GNB2L1 was also co-
transformed with the carboxy terminal of AGTR2 both in AH109 yeast and by co-
immunoprecipitation.  GNB2L1 was found to positively interact with the AGTR2 C-
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terminal in yeast, (see Figure 2.2) and by co-immunoprecipitation (Figure 2.5, lane 1).    
NGLY1 and ASMTL were also found to interact with the C-terminal of AGTR2 via 
co-immunoprecipitation.  When co-transformed with the C-terminal construct in 
AH109 yeast, ASMTL did not interact as strongly with the C-terminal construct as 
with N-terminal construct, as indicated by α-galactosidase activity.  Ngly-1 was found 
to only interact with the N-terminal construct in AH109 yeast as it failed to have any 
growth on –AHLTαgal media when co-transformed with the C-terminal construct. 
 
Figure 2.6   CO-IP of AGTR2 C-terminal and positive interactors with c-Myc 
antibody. 1 = GNB2L1 and C-term, 2 = NGLY1 and C-term, 3 = ASMTL and C-
term, 4 = C-term alone. 
 
Expression of AGTR2-interactive genes in patients with AGTR2 gene mutations 
To examine if the AGTR2 mutations affected the expression of the interacting 
partners identified in our study, quantitative RT-PCR was performed using total 
RNA from transformed leukocytes.  Samples were collected from the patient with no   
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AGTR2 expression (CMS0813), her parents (CMS5065 and CMS0814), a patient 
with the G21V mutation (CMS5103) and two patients with the FS at F132  mutation 
(CMS0690 and CMS4481).  Expression of ASTML, GNB2L1 and NGLY1 was 
examined.   The results are shown in Figures 2.6, 2.7 and 2.8. 
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Figure 2.7  Expression of NGLY1 in human transformed lymphocytes.  0690 – 
patient with 395/402Del T deletion, 0813 patient with no AGTR2 expression, 0814 
– mother of 0813, 5065 – father of 0813, 5103 – patient with G21V mutation,  
control female and control male.  Error bars show standard deviation.  Expression is 
normalized to GAPDH. 
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Figure 2.8   Expression of GNB2L1 in human transformed lymphocytes.  0690 – 
patient with 395/402Del T deletion, 0813 patient with no AGTR2 expression, 0814 
– mother of 0813, 4481 – patient with 395/402Del T, 5065 – father of 0813, 5103 – 
patient with G21V mutation, control female and control male.  Error bars show 
standard deviation.  Expression is normalized to GAPDH. 
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Figure 2.9  Expression of ASMTL in human transformed lymphocytes.   0690 – 
patient with 395/402Del T deletion, 0813 patient with no AGTR2 expression, 0814 
– mother of 0813, 5065 – father of 0813, 5103 – patient with G21V mutation and a 
control female.  Errors bars show standard deviation.  Expression is normalized to 
GAPDH. 
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Quantitative RT-PCR indicated that one patient (CMS0690) with the FS at 
F132  mutation had no expression of ASTML.  However, the other FS at F 132  
mutation  patient had expression in the normal range (Figure 2.8).  As the ASMTL 
gene is in the pseudo-autosomal region of the X and Y chromosome, PCR using 
densitometry was used to ascertain whether the patient had two copies of ASMTL.  
PCR of genomic DNA with densitometry indicated that patient CMS0690 has an 
intact ASMTL gene on both the X and Y chromosomes (data not shown).  No 
conclusions were drawn regarding the expression of both the NGLY1 and GNB2L1 
genes, as there was significant variability between all subjects tested (Figures 2.6 and 
2.7). 
 When the RNA expression of GNB2L1  from brains of Agtr2-/y  mouse 
embryos was compared with that of normal ones using quantitative RT-PCR, 
expression was 1.5 fold lower (p = 0.1) in Agtr2-/y mouse brains (see Chapter One, 
page 45).  When examining the same expression in P1  Agtr2-/y  mice, Gnb2l1 was 
slightly higher, but not significantly (p = 0.6).  The two microarray probes 
representing Gnb2l1 showed a 1.3 and 1.2 fold decrease in expression in the Agtr2-/y 
E15 brains, but no significant change at P1.  No mouse homologue is currently 
known for ASTML.  Microarray analysis revealed little difference in expression 
between Agtr2-/y brains for Ngly1 at either developmental stage.  
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Discussion 
 This study identified three proteins, GNB2L1, NGLY1 and ASMTL, that 
interact with AGTR2.  To identify AGTR2 interacting proteins, a human fetal brain 
library was used in a yeast two-hybrid screening system.  These interactions were 
observed in-vivo (yeast 2-hybrid) and in-vitro (co-immunoprecipitation).   
The AGTR2 N-terminal extracellular domain interacted with amino acids 119-
317 of GNB2L1.  This domain, which contains almost the entire coding sequence, 
consists of exons 2 through 8 of GNB2L1 (Figure 3.12).  Quantitative RT-PCR 
showed that GNB2L1 is down-regulated in Agtr2-/y E15 mouse brains, but not in P1 
Agtr2-/y  brains.  This may suggest a specific function for AGTR2/GNB2L1 binding 
that is unique to the earlier developmental period.  
GNB2L1 is a seven bladed beta-propeller protein made of 316 a.a., containing 
seven WD40 repeats and acts as an intracellular adaptor protein (Sklan et al. 2006).  
The GNB2L1 gene is located at 5q35.3, and consists of eight exons that code for a 
cDNA transcript that is 1142bp in length (Wang et al. 2003).  It belongs to the family 
of receptor for activated protein C (RACK) proteins and also belongs to the family 
of WD40 repeat proteins (Wang et al. 2003).    It is expressed highly in many tissues,  
expressing the same size transcript  (Wang et al. 2003).    
  Both AGTR2 and GNB2L1 are expressed at different levels at different 
stages of development in the embryonic and fetal brain, but in the same areas.   
GNB2L1 (RACK1) and AGTR2 are first expressed at mouse embryonic day 
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11.5(Nuyt et al. 1999; Ashique et al. 2006).  GNB2L1 is expressed in a gradient 
throughout the developing brain and is highest in the telencephalic areas (Ashique et 
al. 2006).   AGTR2 is expressed at moderate to low levels in the telechephalon late in 
fetal development,  but at higher levels in developing brain areas concerned with 
motor functions (Nuyt et al. 1999).  Western blot comparison of hippocampal lysates 
from E13.5, E18.5 and P21 mice probed with anti-RACK1 antibody show a gradual 
decrease of RACK1 expression in the hippocampus through development (Ashique 
et al. 2006).    In postnatal and adult brains both GNB2L1 and AGTR2 are highly 
expressed in the cerebellum and both are expressed in the hippocampus(Ashique et 
al. 2006; von Bohlen und Halbach and Albrecht 2006).  This may indicate a role for 
an interaction of AGTR2 and GNB2L1 in the development of the hippocampus.  At 
the cellular level, GNB2L1 and AGTR2 are expressed in neural cells but not glial 
cells (Gendron et al. 2003; Ashique et al. 2006).  Together these findings support a 
likely role for the interaction of GNB2L1 and AGTR2 in brain development and 
function. 
   GNB2L1 is a scaffolding protein that has many functions including affecting 
other scaffolding proteins, cell adhesion, NMDA activation and dopamine transport 
(Sklan et al. 2006). NMDA receptors are important to synaptic plasticity, learning 
and memory and neuronal development (Dang et al. 2006).  GNB2L1 has been 
shown to inhibit the function of NMDA receptors by binding Fyn, the substrate for 
the NR2B subunit of NMDA receptors (Yaka et al. 2002). 
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 AGTR2 has previously been shown to have effects on neurite outgrowth and 
cell differentiation probably through rearrangements of the cytoskeleton (Gendron et 
al. 2003).  Recently it has been demonstrated that GNB2L1 binds to human 
angiotensin II receptor-associated protein (AGTRAP) which in turn interacts with 
the C-terminal of AGTR1 acting as an inhibitor of AGTR1 signaling (Wang et al. 
2002).  The study described here demonstrated that GNB2L1 interacts with the 
AGTR2 receptor at both the C-terminal and N-terminal in yeast 2-hybrid 
interactions and co-immunoprecipitation. 
AGTR1 and AGTR2 counter-balance the actions of each other physiologically 
(von Bohlen und Halbach and Albrecht 2006).   AGTR2 has been shown to be a 
direct antagonist of AGTR1 in COS-7 and rat fetal fibroblasts (AbdAlla et al. 2001).   
It is possible that the GNB2L1 /AGTRAP complex could be a mediating complex 
for AGTR2 and AGTR1 in some tissues.  Such speculation would require additional 
studies.   
The AGTR2-interacting protein N-glycanase 1, (NGLY1), is a 654 amino acid 
protein that is thought to participate in the degrading of misfolded glycoproteins by 
the proteasome (Suzuki et al. 2003).   The NGLY1 gene is located on human 
chromosome 3p24.2, is 64,226 bp in length consisting of 11 exons.  It consists of a 
PUB, transglutaminase and PAW domains (Allen et al. 2006).    It is primarily a 
cytosolic protein (Park et al. 2001) and is expressed in the heart, brain, liver, kidney 
and testis and is highly conserved in eukaryotes (Suzuki et al. 2003).  This screening 
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found that the amino terminal of AGTR2 interacts with the last 85 amino acids of 
NGLY1 in its C-terminal, the PAW domain (Figure 2.9).  
 Mouse Ngly1 has also been shown to interact with mouse Hr23b, (the mouse 
homologue of yeast Rad23p) which links Ngly1 to the proteasome (Park et al. 2001).   
The same study also found that mouse Ngly1 interacted with mouse S4, which is a 
19s proteasome subunit,  and  required the N-terminal domain of Ngly1 for the 
interaction.  The N-terminal domain is a PUB domain that is unique to mammals 
(Park et al. 2001; Allen et al. 2006).  Park and co-workers (2001) proposed that Ngly1 
may recruit proteins interacting with the ubiquitin proteasome and link them to the 
26S proteasome for degradation of unfolded glycoproteins.  Li and associates 
confirmed this hypothesis by finding that Ngly1 forms a complex with p97, Amfr, 
mY33K and mHr23b to combine ubiquination and deglycosylation actions that send 
misfolded glycoproteins to the proteasome (Li et al. 2005; Li et al. 2006). 
 AGTR2 is a glycosylated protein whose N-linked oligosaccharide side chains 
vary according to the tissue in which it is expressed (Servant et al. 1996).    Some 
membrane proteins have to be N-glycosylated for cell surface expression (Servant et 
al. 1996).  While the N-terminal of AGTR2 is necessary for the binding of 
angiotensin II (Servant et al. 1997),  glycosylation is not necessary for cell surface 
expression or angiotensin II binding (Servant et al. 1996).  If deglycosylation does 
not affect these processes, does NGLY1 bind with AGTR2 as part of the process of 
apoptosis through the proteasome?   Our microarray analysis of mouse E15 and P1 
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brains from Agtr2-/y  and control mice (see Chapter 1)  found several genes involved 
in the ubiquitin/proteasome pathway dysregulated, providing  evidence that may 
suggest that AGTR2 may also be involved with the proteasome. 
ASMTL is a 629 amino acid protein that is not well characterized.  This gene 
maps to the pseudo-autosomal region Xp22.3 and Yp11.3 (Ried et al. 1998).  The 
amino terminal of AGTR2 interacted with amino acids 487- 621 the methyl-
transferase domain of ASMTL (Figure 2.8).  This domain catalyzes the reaction of S-
adenosyl-L-methionine and N-acetylserotonin to S-adenyl-L-homocysteine and 
melatonin.   ASMTL is widely expressed in all tissues except adipose or nerve tissue 
(UniGene/database).  RNA expression of this gene was found to be absent in one 
patient with a FS132  mutation in AGTR2, but not in his affected maternal cousin 
with the same mutation.  Other patients with AGTR2 mutations had expression 
within the range of normal controls (Figures 2.8). 
Further study is needed to describe the function of the ASMTL gene with 
AGTR2.  Co-localization studies in cell lines could further illuminate where both 
genes interact in the cell. It would be also interesting to investigate whether the 
interaction of ASMTL and AGTR2 is unique to the developing brain. 
This study did not find any interaction of the AGTR2 C-terminal with the fetal 
brain library.  While other studies have found this domain to interact with specific 
proteins, none of those studies utilized a fetal brain library.  Interactions with the C-
terminal domain were found in-vitro however, and this may due to co-
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immunoprecipitation being a more sensitive assay than in-vivo yeast 2-hybrid 
screening.  Even though protein production of the C-terminal construct was verified 
by western blot, technical problems cannot be ruled-out. 
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Figure 2.10  Graphical representation of the portion of each positive clone that 
interacts with the amino terminal of AGTR2.  Most of the ORF of GNB2L1 was 
present in the prey construct.  Only the PAW domain of NGLY1 interacts with 
AGTR2 in this study.  The methyltransferase domain of ASMTL interacts with 
AGTR2. 
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With the exception of one patient with no ASMTL expression, no significant 
differences were noted in the expression of candidate genes in the AGTR2 mutation 
patients.  This may be explained by the RNA being collected from leukocytes rather 
than brain tissue, or that these protein interactions are only seen during the fetal 
period.  Mutations in AGTR2 may also have no effect on the expression of these 
genes. 
In summary, this study has characterized three proteins expressed in fetal brain 
that interact with AGTR2.  GNB2L1 is a scaffolding protein, highly expressed 
throughout brain development and has previously been shown to interact with many 
other proteins.  Pathway Studio software was utilized to identify targets common to 
AGTR2 function.  GNB2L1 has many cellular targets in common to both AGTR1 
and AGTR2 (Figure 2.10).  In particular, GNB2L1 binds PTPN11 (aka SHP-2) 
(Kiely et al. 2005) which is down-regulated by AGTR2 (Elbaz et al. 2000) and 
AGTR1 (Marrero et al. 1998).  SHP-2 has been shown to interact with ATIP after 
AGTR2 stimulation, which induces MMS2 expression.  MMS2 plays an important 
role in neural differentiation (Li et al. 2007).  The interaction of AGTR2 and SRC 
has also been shown to influence neural differentiation (Li et al. 2007), 
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Figure 2.11  Pathway Studio (Ariadne Genomics, Rockville, MD) demonstration of 
common targets of AGTR1, AGTR2 and GNB2L1.  Pink shapes = proteins, orange 
octagons = functional groups, yellow squares = cellular functions, purple lines = 
binding, blue lines = expression, gold lines = protein modification, grey lines = 
regulation.  Direction of arrows indicates up-regulation.  Straight line instead of an 
arrow indicates inhibition.  Small squares on lines are references than can be accessed 
via the Pathway Studio program. 
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and SRC is shown to be bound by GNB2L1.  Also, GNB2L1 and AGTR1 are 
involved in the insulin pathway through insulin II (INS) and the insulin growth 
factor one receptor (IGF1R).  AGTR2 and GNB2L1 are connected in the insulin 
pathway through insulin receptor substrate one (IRS1).   
NGLY1 cleaves oligosaccharides and participates in the proteasome.  
Perhaps it is involved with AGTR2 in apoptosis via the ubiquitin-proteasome 
system.  ASMTL has an unknown function, but has a methyltransferase domain that 
interacts with AGTR2. 
  As AGTR2 is expressed in different brain areas depending on developmental 
stage, it would be interesting to investigate the expression pattern of NGLY-1 and 
ASMTL in the developing brain also.  These newly identified AGTR2 interactors add 
to the complex picture of AGTR2 function in the developing brain. 
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CHARACTERIZATION OF THE AGTR2 INTERACTING PROTEIN (ATIP) 
 
 
 Several previous studies have identified different AGTR2 regions responsible 
for the interaction with other proteins involved in AGTR2 activation and regulation.  
The cytoplasmic intracellular domain of AGTR2 has been shown to contain a 
binding domain for ERBB3 (Knowle et al. 2000), PLZF (Senbonmatsu et al. 2003) 
and NHE6 (Pulakat et al. 2005).  In an effort to better the signaling mechanisms of 
AGTR2, Nouet and colleagues (Nouet et al. 2004) identified a novel interacting 
protein called the AGTR2 Interacting Protein (ATIP) that interacted with the C-
terminus of AGTR2.  Subsequently the human homologue was isolated from a 
human lung cDNA library and mapped to 8p21.3 (Nouet et al. 2004).  Northern 
analysis probed with the 354bp cDNA identified as the ATIP interacting domain 
(ATIP-ID) revealed a 1.9 kb transcript in all tissues (spleen, thymus, prostate, testis, 
ovary, small intestine and colon) tested.  It was determined that ATIP had four 
transcripts with varying lengths in the N-terminal domain, but all containing the 
ATIP-ID and C-terminal domain.  Functional studies revealed that the binding of 
ATIP to the AGTR2 cytoplasmic tail inhibited cell proliferation (Nouet et al. 2004).  
This gene was found to be identical to the already annotated gene Mitochondrial 
Suppressor Gene One (MTSG1). 
 Subsequently,  Wruck and co-workers (Wruck et al. 2005) identified the 
ATIP mouse homologue, termed ATB50,   in a yeast two-hybrid screen with the C-
terminus of AGTR2.     The protein had 440 amino acids. These authors found this 
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protein and AGTR2 are co-expressed in mouse tissue.  In addition, in-situ 
hybridization of AGTR2 knockout mouse tissues revealed the expression of 
ATBP50 was less than 10% of that of normal animals (Wruck et al. 2005).  Studies in 
COS-7 cells with fluorescent markers showed that ATBP50 proteins localized to the 
golgi matrix.  Using siRNA they found that the ATBP50 isoform is necessary for 
surface expression of AGTR2.   
The Wruck group (2005) also found that the ATBP50 isoform is the result of 
alternative splicing, as all three isoforms they identified had exons 7 to 15, but 
ATBP50 uniquely contained exon 6.    The other two isoforms identified, ATPBP60 
and ATPBP135 were not found to be expressed in the brain and spleen nor did they 
interact with AGTR2, as ATBP50 did.  These authors also found that stimulating 
PC12W cells with angiotensin II causes a strong expression of ATBP50 (Wruck et al. 
2005). 
 Di Benedetto and colleagues described the genomic structure and expression 
patterns of the human ATIP (Di Benedetto et al. 2006).  The ATIP gene spans 112 
kb consisting of 17 exons and maps to chromosome 8p21.   Five transcripts: ATIP1, 
ATIP2, ATIP3a, ATIP3b and ATIP4  were identified.  The ATIP1 isoform is the 
most predominately expressed isoform in adult brain and is a 436 amino acid 
protein.    ATIP2 is a 770 amino acid protein  found to be expressed at very low 
levels in all tissues examined.  The isoforms ATIP3a and ATIP3b are large 
transcripts and are expressed in many tissues, but at low levels in the adult brain.   
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ATIP3a and ATIP3b consist of 1270 and 1216 amino acid proteins respectively.  
ATIP4, the only form expressed in fetal brain, is a 517 amino acid protein.   It is also 
expressed at relatively high levels in the cerebellum in the adult brain.  The genomic 
structure of each isoform is summarized in Figure 3.1. 
 
 
Figure 3.1  Exon structure of ATIP isoforms.  White boxes indicate exons common 
to all transcripts.  Black box indicates ATIP1 specific exon.  Hatched boxes indicate 
Exons used by ATIP3 and/or ATIP 4 transcripts.  Note that exon five is unique to 
ATIP4.  (Figure used by permission from Di Benedetto et al. 2006 figure 1A). 
 
 In this study the potential for ATIP to be a causal gene for MR was explored.  
The ATIP4 isoform was of particular interest as it is the only isoform expressed in 
the fetal brain, having the potential to interact with AGTR2 and affect brain 
development.  Brain expression was elucidated through the use of Northern blots of 
sections of adult brain.  A mutation screening of ATIP in patients with MR was also 
undertaken.   
    The seventeen exons of ATIP were analyzed in 80 patients.  Particular 
attention was given to the screening of exon 5 because of its unique expression in 
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fetal brain.  Exon 5 was screened in 500 patients with MR.   We found no significant 
mutations in any of the patients screened. 
Methods 
Northern blots and probes  The ATIP-ID  354 bp probe was made by amplifying 
human cDNA with the following primers:  F- 5’ CAGGCTGAAAAAA-
CAGAACGA  3’and R- 5’ TTTTTCATTTAAAGCATCATT 3’. PCR conditions 
were as follows:  Denaturation at 95ºC for 5min.  then 95ºC for 30 sec., 55ºC for 30 
sec., 72ºC for 30 sec. for 30 cycles followed by a 7 min. extension at 72ºC.   The 354 
bp 32P labeled product was hybridized to Northern blots containing poly A+ RNAs 
from different human brain sections (from individuals of ages 16-75 years) 
(Clontech) using ExpressHybe (Clontech) at 65ºC for 1 hour after pre-hybridizing at 
65ºC for 2 hours.  The filters were washed with of 2X SSC-0.05% SDS solution at 
65ºC for 40 minutes and then with 0.1X SSC-0.1% SDS solution at room 
temperature for 20 minutes.  The filters  were exposed to Biomax film (Kodak) 24 
hours and for 5 days at -80ºC. 
Mutation screening   Mutation analysis was performed using Denaturing High 
Pressure Liquid Chromatography (DHPLC) or Incorporation-PCR Single-Strand 
Conformation Polymorphism (IPS).   Amplicons were amplified with the primers 
listed in Table 3.1 (primer sequences were provided by Dr. C. Nahmias) by using 1 
ng of genomic DNA with 1X PCR buffer, 125 µM dNTPS, 1 µCi of  αP33  dCTP 
(3,000Ci/mmol), 0.5 µM of each primer and 1U of GO Taq™ polymerase 
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(Promega) in a 10µl reaction.  PCR conditions were as follows:  95ºC for 5 min. 
followed by 95ºC for 30 sec., appropriate annealing temperature for 30 sec., 72ºC for 
30 sec. for 30 cycles followed by a 7 minute extension at 72ºC.  Ten microliters of 
formamide/NaOH  BPB buffer was added to each sample and then they were 
denatured at 95ºC for 5’ and placed on ice.  Samples were loaded on a 6% MDE gel 
(FMC) and run at constant power of 8W from 16-20 hours.  Gels were dried and 
visualized with X-Ray Biomax film (Kodak) at room temperature.  Samples that 
demonstrated a banding pattern or shift that differed from normal controls were 
selected for sequence analysis. 
 Amplicons selected for DHPLC were amplified using 20 ng of human 
genomic DNA, 1X PCR buffer, 250µM dNTPs,  1.0 µM of each primer and 1U of 
GO Taq™ polymerase (Promega) in a 20 µl reaction.   Five µl of each PCR mix was 
run on a 1.8% agarose gel to verify the amplicon.  Samples were then pooled in 
groups of four.  Pooled samples were heteroduplexed by heating to 94ºC for seven 
minutes and then 55ºC for four minutes.  DHPLC conditions based on the melting 
temperature of each amplicon were selected using the Wavemaker program 
(Transgenomics).  Chromatography using the appropriate temperatures was 
performed and their denaturing profiles were inspected visually. 
Samples that showed a profile differing from normal controls were selected for 
further analysis.  The four individuals from the abnormal pooled sample were PCR 
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amplified and then subjected separately to DHPLC analysis.  The individual sample 
that differed from the normal control was selected for sequence analysis. 
  Samples selected for sequencing from either IPS or DHPLC were amplified 
by using 100 ng DNA genomic DNA, 1 X PCR buffer,  0.5 µM of dNTPs, 1.0 µM 
of each primer and 2U of GO Taq™ polymerase in a 50 µl reaction.  PCR products 
were purified and both strands were sequenced using the DYEnamic ET Dye 
Terminator Cycle Sequencing Kit (GE Healthcare) and the automated MegaBACE 
1000 DNA analysis system (GE Healthcare).  Sequences were analyzed using the 
DNASTAR program (Madison, WI USA). 
Table 3.1 
Primers for ATIP Gene Screening 
 
Exon Primer sequence   5’ – 3’ annealing temperatureºC product size (bp)
Exon 1.1 F:  GACAGACCATTTTGCCCACCCTCTC R : CAACTGTGTTGCAGATATTTGGGC 64 444 
Exon 1.2  F : GTAAGCAGGTGTTAGATATGC R : GGCTTCTGATGGTGTGACTTGAGG 55 443 
Exon 1.3 F : CATCTTCCCATTCTGATAAGACGC R : CATCAATAAGACAATAGGAC 55 417 
Exon 1.4 F : GCTCATACAGGCACAAGGAAATGG R : GTCTGGTATGTTTTTAAGCCCTCG 55 413 
Exon 1.5 F : GTTTCACCGATTGAAGCGACGG R : GAATGAGTTGTAACATGCACAGCC 64 458 
Exon  1.6 F : TAACAAGACACATAAGCAGCAG R : GCTAACACATCTCAGTTTTCTCC 55 446 
Exon 2 F : GGGGCCCATTCAGTCAGTTG R : GACCTATAATCATGACTGTCC 55 356 
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Table 3.1 (continued) 
 
Exon 3 F:  GATAGCCTATTGTCCTAATGG R:  GCAAGAGAGCAGAAATGATGAGGC 55 224 
Exon 4 F : CTTAAAAAGTGCCAGCTTTCGGG R : CATTAGTTTTTCTTGTAATGACTG 55 290 
Exon 5 F : CATGTTGACTTGGCCACCGTTTC R : AAATTTAAGCATGCTTACAAAG 53 585 
Exon 6 F : GGACAAAGGAATAAATGTGG R : CAAGCCAAGGACTTTAAGCG 55 269 
Exon 7 F :CCGGGAACCTGAAATGTAGCG R : GGAAATTCTACTTATAAGCACACC 62 267 
Exon 8 F : GAGACCACCCACTTTCTCCTCCCC R : GCAAATTAATGAAGACATCCCCC 57+DMSO 539 
Exon 9 F:  GTTTTTGAATCCTTGTGGTGG R:  GCGTGTGAGCAAGTCCTCCCCG 56 364 
Exon 10 F : GCCTAAATGATTCATATCTTGGC R : AACAGCTCCCAGCATGCAACTCC 56 298 
Exon 11 F : GTATGCTTCAGGTGTCATCACAGC R :CCTATTAGACTAAAAAAGAGAAGCTC 57 408 
Exon 12 F : GCCTTTAAACTAGAGCCCACGC R : CCACAGGGCATTCGCTGAAGCAGG 59+DMSO 336 
Exon 13 F : GGCTTCATCATCAACCCC R : CGTACACAGAAACATTAAAACC 57+DMSO 259 
Exon 14 F : CGTATGCTGAGTTTCTGGGGTT R : TGTTATTTCTCTGGCTGCTG 59+DMSO 248 
Exon 15 F : CGCTTGCTACTTGTCTAATGTC R : ATAAATATGGAACAAACTTGGA 56 387 
Exon 16 F : TTTTTCAGTATGTTTGTTAGTGT R : GCAGGGGTAGAGCGTGTCCAGA 57 340 
Exon 17 F : GCCAAATACCTGTGACCTTGTGC R : CCCACGTTCCTCCTTGGGG 60 438 
 
Characterization of a heterozygous deletion  Sequencing of both DNA strands of a 
patient with an alternatively migrating fragment of exon 14 produced very poor 
sequence results.  This was thought to be due to a deletion.  To confirm the deletion, 
sequencing of both strands was undertaken.  To separate the leading and lagging 
strands, the exon 14 amplicon was subcloned into the pCR2.1 vector in the TA 
Cloning Kit (Invitrogen) as described in Chapter 2.  Ten clones containing inserts 
were selected and DNA was prepared.  Purified plasmid DNA from these clones was 
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sequenced as described previously using the following primers: M13F 5’ 
CTGGCCGTCG-TTTTAC 3’ and  M13R 5’ GTCATAGCTGTTTCCTG 3’.  
Sequences were analyzed with DNASTAR (Madison WI, USA).  This technique 
allows for clean sequencing by separating the leading and lagging strands. 
Mutation screen via restriction enzyme digest  To screen for a possible polymorphic 
variant in exon 14, 120 normal controls and the patient with a 4 bp intronic deletion 
were amplified with exon 14 primers in a 25 µl PCR reaction as previously described.  
Ten microliters of the 238 bp product were then digested with 2 U of Hpa I 
restriction endonuclease (New England Biolabs) and 1 X buffer in a 20 µl reaction 
and incubated at 37ºC for at least 4 hours.  The digest was run on a 3% NuSieve 
agarose gel and visualized with ethidium bromide on a UV illuminator.  The deletion 
destroys the Hpa I site and thus a deletion has a 238 bp band instead of 219bp and 
19 bp band.  Heterozygotes would have a 238 bp, 219bp and 19 bp bands. 
Results 
Expression of the ATIP gene in brain 
Expression of ATIP has been shown in human brain (Di Benedetto et al. 
2006).  To monitor the expression pattern in brain regions in humans, a Northern 
blot containing RNAs from the different regions of the adult human brain was used.  
A cDNA probe containing the ATIP-ID coding region was hybridized to  human 
adult brain Northern blots (Clontech).  The ATIP-ID was found to be expressed in 
all brain tissues.  A transcript of 4.4 kb was found in all tissues examined.  A 
  90                         
relatively weakly expressed transcript of 7.4 kb was also seen (Figure 3.1).  
Expression appeared to be highest in the corpus callosum, cerebellum and thalamus 
(Figure 3.1).   
PCR of a human fetal brain library with ATIP-ID primers found that this 
domain was not expressed in the library made from 20-25 week human fetal brain.  
However, the unique transcript, containing exon 5, was expressed (data not shown).  
Mutation screening and detection of nucleotide variants in the ATIP gene 
The ATIP gene contains 17 exons.   All exons were screened in female 
patients with MR.  These patients previously tested negative for the MR causing 
FMR1 gene expansion.   Two normal controls and 80 or 160 patients were screened 
using either IPS or dHPLC (Table 3.2).  Patients with alternatively migrating 
fragments were selected for sequencing.  Six patients were found to have a 
c.1791A>C (p.K435T) alteration in exon one.  This alteration was also found in 8 of 
90 normal male controls.  One patient carried a heterozygous deletion of five 
nucleotides (ivs13-22del5).  Subsequently, this patient was found to have San Fillipo 
syndrome through biochemical testing and thus this deletion is unlikely to be MR  
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Figure 3.2  Expression of ATIP isoform in the human  brain.  Northern blots 
(Clontech) containing RNA from different human adult brain sections were 
hybridized with a 354 bp ATIP cDNA probe. 
 
causing in this patient.  This patient’s deletion was elucidated by subcloning  the 
exon 14 amplicon and then sequencing a number of insert-containing plasmids.  By 
this technique the leading and lagging strands were separated and single-strand 
sequencing was accomplished.  The sequence chromatogram of this patient’s normal 
and deleted exon 14 are shown in Figure 3.3.   A summary of the mutation screening 
is detailed in Table 3.2.   
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Figure 3.3  Electropherogram of aligned exon 14 from patient with a 5 bp deletion.  
The normal strand is on the top row, the deleted strand in on the second row and 
the ATIP exon 14 sequence is on the lower row.   
 
Table 3.2 
Mutation Screen Summary for ATIP 
 
Exon 
Number 
of 
Patients 
Screened 
Nucleotide 
Change 
Amino 
Acid 
Change 
Number 
of  
Patients 
with a 
shift 
Number 
of 
controls 
with a 
change 
Screening 
Method 
1 80 c.1791A>C p.K453T 6 8 of 90 DHPLC 
2 80 none  0  DHPLC 
3 80 none   7*  IPS 
4 80 none  0  IPS 
5 160 none  0  DHPLC 
6 160 none  0  DHPLC 
7 160 none   1*  DHPLC 
8 160 none  0  IPS 
9 80 none  0  DHPLC 
10 80 none   2*  IPS 
11 80 none   1*  IPS 
12 80 none  0  IPS 
13 80 none    1*  IPS 
14 80 IVS13-22del5 No 1 0 of 120 IPS 
15 80 none  0  IPS 
16 80 none  0  DHPLC 
17 80 none  0  DHPLC 
*No nucleotide changes were found in these samples. 
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Discussion 
Northern blots of adult brain tissues probed with the ATIP-ID cDNA found 
a 4.4 kb transcript and a weakly expressed 7.4 kb transcript.  Expression was 
comparatively higher in the corpus callosum, cerebellum and thalamus.  Expression 
was noticeably absent from the spinal cord.  No expression of the ATIP-ID was 
detected in the human fetal brain library.   However, the fetal brain library did 
contain cDNA from exon 5, which is specific to the fetal brain isoform of ATIP.  
No significant alterations in an initial screen of our MR population were found. 
Interestingly,  the Atip gene was not found to be dysregulated at either 
developmental stage in Agtr2-/y mice.  Microarray analysis of Agtr2-/y  mice (see 
Chapter One) revealed no significant difference in the expression of Atip (alias 
Mtus1) from normal controls.   
  The initial discovery of ATIP was found through a yeast 2-hybrid screen 
using the last 52 amino acids of AGTR2 as bait against a mouse fetal cDNA library.  
The cDNA region that encoded the 118 amino acids found to interact with AGTR2 
was designated the ATIP-ID 
The ATIP4 isoform containing exon 5 is the only isoform of ATIP found to 
be expressed in fetal brain.    This isoform is also expressed in the adult brain, 
predominately in the cerebellum, but is not found in any other tissues (Di Benedetto 
et al. 2006).   Previous analysis of the same adult brain blots used in this study with 
AGTR2 cDNA as a probe, found expression only in the cerebellum (Vervoort et al. 
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2002).    This is also consistent with the high expression of the ATIP-ID found in 
the cerebellum on this study’s northern blots (Figure 3.1).  It might be possible that 
the interaction of ATIP and AGTR2 is limited to the cerebellum. 
Using the C-terminal of mouse Agtr2, Wruck and colleagues, ( 2005) found a 
full-length cDNA designated ATBP50,  a gene analogous to human  ATIP. ATBP60 
and ATBP135 were two other ATB isoforms and were found not to interact with 
AGTR2.  While all three isoforms contained exons 7 to 15, Atbp50 uniquely included 
exon six, which is analogous to human ATIP exon eight.  Di Benedetto and co-
workers discovered that ATIP exon 5 (isoform ATIP4) has a 90% homology to 
ATBP60 and ATIP1 unique exon 8 has an 87% homology to ATBP50 (Di 
Benedetto et al. 2006).  It is interesting to note that the only described mouse 
isoform able to interact with AGTR2, ATBP50, is analogous to adult brain ATIP1.  
The mouse isoform analogous to fetal brain expressed ATIP4 (ATBP60), was not 
shown to interact with AGTR2 (Wruck et al. 2005).  
Co-expression of Atbp and Agtr2  in tissues of  Agtr2-/y mice was examined by 
Wruck and colleagues (Wruck et al. 2005) via is-situ hybridization and quantitative 
RT-PCR.   Using a probe common to all three isoforms, they examined co-
expression of Atbp and Agtr2 in adrenals, kidney, lung, heart and brain from adult 
control and Agtr2-/y mice.   They found expression patterns of both genes to be 
similar in all tissues examined.  Using uterine tissue from control and Agtr2-/y animals, 
they also found that the expression of Atbp  was less than 10% of normal in Agtr2-/y 
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mice.  The microarray results seen in our study were from brains of control and 
Agtr2-/y  E15 and P1 mice and no difference was seen between the two groups.  This 
may be explained by the ATBP50 isoform not being expressed in fetal brain. 
The mutation screen of the patient cohort analyzed in this study did not find 
any disease causing mutations.  ATIP exon 5 specific to the isoform expressed in 
fetal brain, was screened for a larger cohort of 500 patients with MR.  Mental 
retardation is a heterogeneous disorder that is likely caused by many factors.  
Mutations in causal genes of MR are rare and are often found at a low frequency.  
Thus a larger number of patient samples would need to be screened before ruling 
out ATIP as a gene involved in MR.  Further investigation of the function of the 
ATIP isoform specific to fetal brain may also be pursued to further clarify its role in 
developing brain. 
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CONCLUSIONS 
 
 
The functions of AGTR2, a receptor for angiotensin II,  are still not fully 
understood.  While better characterized for its role in blood pressure regulation and 
fluid homeostasis, the brain functions of AGTR2 are just beginning to be explored.  
The fact that AGTR2 is expressed at higher levels, and in different areas, in the fetal 
brain as compared to the adult brain, point to its function in brain development.  
The purpose of this study was to further elucidate the function of AGTR2 in the 
developing brain. 
 In Chapter One we explored the differences in gene expression between E15 
and P1 Agtr2-/y and control mouse brains.  Abnormal dendritic spine morphology 
and cell number had previously been observed in Agtr2-/y mice.  RNA from eight 
knockout and six control E15 brain samples was hybridized to 16 Agilent Whole 
Mouse Genome 44K arrays.  Data from these arrays was used to produce a  list of 52 
up-regulated and 10 down-regulated genes in E15 Agtr2-/y  mouse brains.  RNA from 
four Agtr2-/y and four control P1 brain samples were also hybridized to eight arrays.  
Data from this experiment produced a final list of 50 up-regulated and 12 down-
regulated genes in P1 Agtr2-/y  mouse brains.   Results were verified via quantitative 
RT-PCR. 
  The gene expression profiling analysis in the study revealed a number of  
genes involved in microtubule regulation, protein binding, cell adhesion, 
transcription, DNA binding and kinases up-regulated in developing brain.  
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Transferases, as well as a large number of transcription factors, were up-regulated in 
E15 Agtr2-/y mouse brains.  Unique to the P1 Agtr2-/y mouse brains were genes 
involved in glutamate metabolism, cell cycle control and RNA metabolism.  Our 
findings add strength to the hypothesis that AGTR2 contributes to the developing 
brain by influencing cell morphology and synaptic connectivity. 
In Chapter 2, three AGTR2 interacting proteins, GNB2L1, NGLY1 and 
ASMTL were identified.  These proteins were found by screening a human fetal 
brain library with the N-terminal domain of AGTR2.  These interactors were also 
verified by co-immunoprecipitation.   A weak interaction was also noted for 
GNB2L1 and ASMTL with the C-terminal of AGTR2.  The interaction of NGLY1 
was specific to the N-terminal of AGTR2.  GNB2L1 is a scaffolding protein with 
many functions, and has been shown to be involved in the signaling cascade in the 
central nervous system. GNB2L1 may interact with AGTR2 as part of a gene 
network that contributes to neuronal differentiation.  ASMTL gene function is 
largely unknown.  NGLY1 participates in degradation of misfolded glycoproteins by 
the proteasome.   A role for AGTR2 in apoptosis has been described.   We 
hypothesize that NGLY1 in association with AGTR2 may be involved in apoptosis 
through the ubiquitin-proteasome. 
 In Chapter 3,  a partial characterization of a previously identified AGTR2 
interacting protein, ATIP, has been discussed.  This gene was explored as a potential 
MR candidate gene as it has been shown previously to interact with AGTR2 and is 
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expressed in the brain.  Northern blot analysis of adult human brain tissue found 
that the region encoding the ATIP interacting domain (ATIP-ID) is expressed in all 
brain tissues.    The expression of the Atip gene was not dysregulated at either 
developmental stage of the Agtr2-/y mice, possibly indicating that the interaction of 
the ATIP isoform with AGTR2 is likely not to be crucial to brain development.   
Furthermore, in a human mutation screening we did not identify any MR 
disease causing mutations in 80 patients analyzed.  Further investigation of the 
function of brain specific isoforms of ATIP my further clarify its role in brain 
function.  
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Mapping of X;7 Translocation in a Female Patient with MR and No AGTR2 
Expression 
 
Introduction 
 
 A female patient with moderate to severe mental retardation (IQ 44)  was 
previously found to have a de novo t(X;7)(q24;q22) translocation.   The patient has 
totally skewed X inactivation in favor of the translocated X chromosome, as 
compared to random X-inactivation in her mother with two normal copies of the X 
chromosome.  Because causative genes are present at long distances in several 
disease-associated balanced translocations, expression studies of candidate genes for 
the X breakpoint region were performed.  This revealed that this patient had no 
expression of AGTR2.  A subsequent screening of affected males from 33 families 
with possible X-linked mental retardation and 552 unrelated males with mental 
retardation found nine patients with mutations in AGTR2 (Vervoort et al. 2002).  
The X breakpoint region was mapped 150 kb proximal to the AGTR2 gene. The 
AGTR2 gene was found not to be disrupted.   It was hypothesized that the loss of 
expression in the patient with the t(X;7) may result from separation of distant 
regulatory elements.  Through Fluorescent In-Situ Hybridization (FISH), pulsed-field 
and southern blot analysis and Comparative Genomic Hybridization (CGH) it was 
determined that the X breakpoint was in a region of a pseudogene near the DXZ4 
locus (Vervoort et al., unpublished work).  The CUTL1 gene was putatively 
disrupted on chromosome 7, but it was determined that the patient had expression 
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of this gene from her normal chromosome 7.  In this study the Xq24 and the 7q22 
breakpoint were partially mapped. 
Materials and Methods 
Florescent-InSitu Hybridization (FISH)  Lymphocytes from patients were 
transformed with EBV and cultured until confluent.  BAC clones were selected by 
searching the breakpoint region using the NCBI MapViewer 
(http://www.ncbi.nlm.nih.gov/mapview/).   BAC clones purchased from Chori or 
Invitrogen were grown on LB media with chloramphenicol as described in previous 
studies.  Individual colonies were cultured in LB media with chloramphenicol  and 
the plasmid DNA isolated using Qiagen Mini-Prep columns as previously described 
in Chapter 2.  DNA was labeled by incorporation of digoxigenin-11-dUTP 
(Boehringer Mannheim) by nick translation using DNA polymerase I (Life 
Technologies).  Metaphase chromosome spreads were obtained from harvested 
patient lymphoblast cell lines and FISH was performed using standard methods 
(Vervoort et al. 2002).  The labeled probes were visualized with rhodamine-labeled 
anti-digoxigenin and the chromosomes were counterstained with DAPI.  Images 
were examined under a Zeiss Axiphot fluorescent microscope.  
Pulsed-Field and Southern Blot Hybridization  (Pulsed-field gel Southern blots 
were made by V. Vervoort). Total genomic DNA (100ng) was digested with EcoRI 
(New England Biolabs) and electrophoresed on a 0.8% agarose gel.  The gel was 
denatured and transferred to a Hybond (GE Healthcare) charged nylon membrane 
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using alkaline 3M NaCL 0.4M NaOH transfer method.  After transfer was complete, 
membrane was baked at 65ºC for one hour and  pre-hybridized with  hybridization 
solution (4x SSPE, 2X Denhardt’s solution, 0.5% SDS, 6% polyethyleneglycol, 40 
mg/ml denatured salmon sperm DNA) at 65ºC for at least 2 hours.  Fresh 
hybridization solution was then added.  DNA probes were labeled with 32P d-CTP  
using the Redi-Prime Random Labeling kit (Invitrogen) according to manufacturer 
instructions, and then hybridized overnight at 65ºC.  Filters were then washed with 
5X SSC 0.1% SDS for one min. at 65ºC,  2X SSC 0.1% SDS  for 15 min. at 65º C  
and then for 15 min. at room temperature; and with 1X SSC, 0.1% SDS  for 15 min. 
at room temperature.  Filters were exposed to Biomax (Kodak) film at -80ºC for at 
least 24 hours.  Primers used for amplifying specific probes are listed in Table A.1.  
(Primers designed by V. Vervoort) 
Table A.1 
Primer sequences for Probes 
 
Name Sequence 
5’ to 3’ 
Annealing 
Temp. ºC 
Size 
(bp) 
Probe 7 F-CTCTCACCTGGTCCCCTTATCTCT 
R-GTATGGCCCTGTGGTGGTGTG 
68 1171 
Probe 8 F-TTTCCCCATCCCATCTCCACTTGA 
R-ATCGCTGCCGCCTCCTTCTTCTG 
62 657 
Probe 8B F-CCTCCCCCAACTCTCCCCTTAGC 
R-CTCATATCCGGGACTTGCTGCTCT 
55 715 
Probe 
DXZ4 
F-ACCGGCAAGGGGCTGGGGGAAGAG 
R-TGAAGGCGCACGTGGGCAAGAAGT 
68 2334 
 
Comparative Genomic Hybridization Analysis CGH was carried out using an 
Agilent 44K Human Genome Chip (Agilent).  Patient and control DNA were first 
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quantified to be of equal concentration and then digested with RsaI, labeled with 
either dUTP Cy5 or dUTP Cy3 (Perkin Elmer) and hybridized according to 
manufacturer protocol. In brief, each CGH slide was hybridized with two DNA 
samples: a control and the patient.  The control was labeled with either dUTP Cy5 or 
dUTP Cy3 and the patient is labeled with the other.  Another slide was also used 
utilizing a dye-swap strategy.  The labeled samples were combined with manufacturer 
provided hybridization solution, spread on the CGH slide, sandwiched with a gasket 
slide and hybridized in a 65ºC oven with rotation for 17 hours.  Slide assemblies 
were then unassembled, washed briefly in SSC washes (Agilent part number 5188-
5221 and part number 5188-5222), washed briefly  in acetonitrile and also in 
proprietary ozone scavenging solution (Agilent part number 5185-5979).  Slides were 
read on a GenePix 4000B scanner and data was extracted and normalized using 
Feature Extraction 8.0 software (Agilent).  Analysis of results was performed using 
CGH Analytics software (Agilent). 
RNA Extraction  RNA was extracted from EBV transformed leukocytes using the 
Qiagen RNeasy kit (Qiagen) according to manufacturer instructions.  Samples were 
then DNased using the Ambion Turbo DNase-free kit (Ambion Inc.).  Samples were 
analyzed on the Agilent 2100 expert bioanalyzer (Agilent) for purity and 
concentration as described in Chapter 1. 
Quantitative RT-PCR  Primers were designed using the Primer3 program from 
MIT (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi) (Rozen and 
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Skaletsky 2000).  Biorad I-Script 1 step RT-PCR with SYBR green (Biorad) was used 
according to manufacturer instructions with 5 ng of RNA per sample used.  Samples 
were run in triplicate on a Biorad i-cycler and analyzed using a standard curve 
method  (Larionov et al. 2005)using GAPDH as a control as described in Chapter 
One. The primers for RT-PCR are listed in Table A.2. 
Table A.2 
Primers for Quantitative RT-PCR of CUTL1 
 
Name Primer Sequence Annealing 
Temp. ºC 
Product 
Size (bp)
Cutl1 F-CGGCAGAGGAAGTACCTGAG 
R-TTCTCGTGGAACTTGTGCAG 
60 233 bp 
GAPDH F-GAAGGTGAAGGTCGGAGTC R-GAAGATGGTGATGGGATTTC 61 225 bp 
 
Results 
Comparative Genomic Hybridization (CGH) is a technique that allows for 
scanning an individual’s whole genome at one time in order to find significant 
changes in gene dosage.    To look for a possible small deletion on either 
chromosome 7 or X of patient CMS0813 with the (tX;7), an Agilent 44K Human 
genome chip (Agilent) was utilized.  This chip has an average probe spatial resolution 
of 35 kb.  No deletions or duplications were found. 
Using FISH probes, the 7q22 breakpoint on the patient’s translocated 
chromosome was narrowed to the CUTL1 gene (Figure A.1).  This was 
accomplished by using probes in succession from the distal (area below the 
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breakpoint in the direction of the telomere) and from the proximal (area above the 
breakpoint in the direction of the centromere) ends of the breakpoint region until a 
probe is found that spans the breakpoint region.  A schematic map of the probes for 
the breakpoint region is shown in Figure A.1. 
 
 
Figure A. 1  Map of FISH clones of 7q22 relative the CUTL1 gene on the 
translocated chromosome 7 of patient CMS0813.   The critical breakpoint region is 
located in the intronic region of the CUTL1 gene.  
 
Since the CUTL1 gene appeared to be disrupted on the translocated chromosome 7 
of patient CMS0813, a cDNA probe of CUTL1 was hybridized to the 
EcoRI/EcoRV pulse-field blot to look for major shifts, but none were found.  This 
complemented the FISH data as the position of the FISH clones indicated that 
majority of the CUTL1 coding region was distal to the breakpoint.  
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To further assess whether the patient’s CUTL1 gene was affected by the 
breakpoint, quantitative RT- PCR analysis of the patient’s and parents RNA was 
performed.  This analysis showed the patient had expression of CUTL1 (Figure A.2).  
Expression was too variable among all samples analyzed including controls to 
accurately assess if the level of patient CMS0813’s expression was affected by the 
disruption of CUTL1.   
 
 
Figure A.2 Quantitative RT-PCR of CUTL1.  CMS0690 = patient with truncated 
AGTR2 receptor, CMS0813 = patient with no functioning AGTR2, CMS0814 = 
control female, CMS5065 = control male, CMS5103 = patient with G21V mutation 
of AGTR2.  All data normalized to GAPDH.  Error bars indicate standard deviation. 
 
A pulse field gel of the digested EcoR1 and EcoRV digest DNA of the 
translocation patient, her parents and controls was created in our laboratory 
previously.   This blot was successively analyzed with several probes derived from 
the Xq breakpoint region.   This analysis revealed a deleted and shifted region in the 
patient’s chromosome X breakpoint area (Vervoort et. al., unpublished data).  A 
probe made from microsatellite DXZ4 was found to be intact (Figure A.3), as well as 
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intronic probe number 7 (data not shown).   Probe number 8, a 657 bp region 
upstream from DXZ4, was found to be deleted in the patient in both the EcoR1 and 
EcoRV digest, as the patient had only her mother’s allele (Figure A..4)  Probe 
number 8B was found to be shifted in the EcoR1 digest with the patient having her 
mother’s allele but missing her father’s allele (Figure A.5).   
 
Figure A.3  EcoRI and EcoRV digest pulse-field blot with probe DXZ4.  Males have 
one band, females have two bands.  Breakpoint patient CMS0813 has one allele from 
each parent with both digests indicating her DXZ4 region is intact. 
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Figure A.4  EcoRI and EcoRV digest pulse-field blot with probe 8.  This probe, 
proximal to probe DXZ4, patient CMS0813 has only her mother’s allele, indicating a 
deletion of her father’s allele. 
 
 
Figure A.5  EcoRI and EcoRV digest pulse-field blot with probe 8B.  This probe, 
proximal to DXZ4 and distal to probe8, shows patient CMS0813 missing her father’s 
allele in the EcoRV digest, but shows a lower, shifted band in the EcoRI digest 
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A map summarizing the position of these probes and their results can be seen in 
Figure A.6. 
 
 
Figure A.6  Map of X breakpoint region for patient CMS0813.  E’s in diamonds 
represent Eco RI cut sites.  Orange probe 8 is deleted and yellow probe 8B detected 
an alternatively migrating fragment. 
 
Southern blot analysis was performed to better elucidate the size of the 
shifted fragment in patient CMS0813 seen with probe 8B on the pulse-field gel 
electrophoresis blot.  The Southern blot analysis showed an approximately 10 kb 
band unique to the patient (Figure A.7). 
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Figure A.7   EcoRI Southern blot with probe 8B, showing 10 kb band unique to 
CMS0813.  No bands were expected to be seen in the parental lanes.  Further 
Southern blot analysis had narrowed the deleted region on the X chromosome in 
patient CMS 0813 to the 3 kb region between probe 8 and probe 8B (data not 
shown).   
 
Sequence analysis of the probe 8 sequence with BLAST revealed this probe 
contained nucleotides 59 to 715 of a predicted gene,  LOC728825 (XM_01128769), a 
pseudogene homologue of SUMO2 located on chromosome 17q25.1.   Some 
pseudogenes have been shown to produce active transcripts (Harrison et al. 2005).  
The cDNA of CMS0813, her parents and cDNA from a human fetal brain library 
was amplified using the probe 8 primers.  All of the cDNA produced a 657 bp 
product and the genomic DNA produced a 657 bp and 700 bp band (figure A.8).  
This second band was produced on several attempts whether the DNA used was 
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from a male or female.  It is most likely due to the primers amplifying both the 
SUMO2 gene and its pseudogene LOC728825.    However, the sequence homology 
between this pseudogene and SUMO2 is too similar to determine if the pseudogene 
produced the transcript. 
 
        
Figure A.8   cDNA PCR products of probe 8 primer.  1 – 100 bp ladder, 2 – 
CMS0813, 3 – CMS0814 (mother), 4 – CMS5065 (father), 5 – fetal brain library, 6 – 
genomic DNA from CMS5065 7 – water lane.  The genomic samples produced two 
bands, likely from the amplification of the SUMO2 gene and the pseudogene.   
 
 Previous works have demonstrated that breakpoints substantial distances 
from disease causing genes can affect the expression of the primary gene (Pfeifer et 
al. 1999; Crisponi et al. 2001).   This may also be the case in patient CMS0813.  It 
remains to be seen if the deleted pseudogene or a genomic element deleted in the 
patient may act as a transcriptional regulator for AGTR2. 
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In conclusion, we were able to determine that the 7q22 breakpoint maps to 
the CUTL1 gene.   Furthermore, the Xq24 breakpoint was narrowed to a 3 kb region 
that contains a pseudogene. 
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